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Abbreviations 
AD Alzheimer´s disease 
BB Blocking buffer 
BBB Blood-brain barrier 
BCSFB Blood-cerebrospinal fluid barrier 
BEC 
BLMB 
Brain endothelial cells 
Blood leptomeningeal barrier 
CC Corpus callosum 
CCL12 Chemokine ligand 12 
CCL2 Chemokine ligand 2 
CCL7 Chemokine ligand 7 
CCR2 Chemokine receptor 2 
ChP Choroid plexus 
cMCAO Permanent distal middle cerebral artery occlusion 
CNS Central nervous system 
CSF Cerebrospinal fluid 
CV Cresyl violet 
DAPI 4′,6-Diamidine-2′-phenylindole dihydrochloride 
EAE Experimental autoimmune encephalitis 
fMCAO Transient proximal middle cerebral artery occlusion 
HE Hematoxylin-eosin 
ICAM-1 Intercellular adhesion molecule-1  
IFN Interferon 
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IgG Imunoglobulin G 
LFA Lymphocyte function-associated antigen 1 
PBS Phosphate buffered saline 
PFA Paraformaldehyde 
pRCT Preclinical randomized controlled multicenter trials 
PSGL-1 P-selectin glycoprotein ligand 1 
PT Phototrombosis 
TBI Traumatic brain injury 
TCR T cell receptor 
Th1/2 Type 1/2 T helper cell 
tMCAo Transient proximal middle cerebral artery occlusion 
rtPA Recombinant tissue plasminogen activator 
Treg Regulatory T cell 
TUNEL Terminal deoxynucleotidyltransferase-mediated dUTP nick-end 
VCAM-1 Vascular cell adhesion molecule-1 
VLA-4 Leukocyte very late antigen-4 
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1. Introduction  
1.1 Stroke and stroke treatments 
Stroke is one of the most common causes of death and is a major cause of disability worldwide. 
Although strokes can be either ischemic or hemorrhagic, 80%–85% of all stroke cases are 
ischemic (Donnan et al., 2008). Ischemic strokes occur in cases in which a brain blood vessel is 
occluded, triggering an irreversible brain injury followed by neurological deficits. Stroke 
symptoms include sudden confusion and numbness of the face, arm or leg, often on one side of 
the body. Also, trouble walking, dizziness, loss of balance or coordination, trouble seeing in one 
or both eyes and difficulty speaking or understanding speech can occur. Although stroke patients 
are a tremendous medical and economic burden, there are few approved treatment options for 
stroke patients. 
The most common drug treatment for ischemic stroke patients involves intravenous thrombolysis 
with alteplase (recombinant tissue plasminogen activator [rtPA]). rtPA selectively hydrolyzes 
plasminogen to plasmin, and this, in turn, leads to the degradation of the fibrin clot. Although 
rtPA has been used for 20 years, this treatment has two significant limitations: 1.) It has to be 
administered within a short time window (3–4.5 h) after the ischemic insults occur, and 2.) It has 
crucial contraindications, including hemorrhage or oral anticoagulation (Hacke et al., 2008; Jauch 
et al., 2013). Furthermore, rtPA has been reported to have low effectiveness in re-stabilizing 
blood flow in large vessel (such as the cerebral or distal carotid artery) occlusions (Bhatia et al., 
2010). For these reasons, rtPA is only administered to a small percentage of stroke patients. 
Mechanical thrombectomy is another approved therapy for stroke patients. Recently, some 
randomized trials of new mechanical thrombectomy devices (coil retrievers, aspiration devises, 
and stent retrievers) demonstrated a probable better outcome for stroke patients compared to that 
of thrombolysis treatment (Dargazanli et al., 2017; Hamidi et al., 2010; Wisloff et al., 2010). 
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However, only a minority of patients are eligible to receive these specific treatment options due 
to the narrow therapeutic time window and multiple exclusion criteria. For the last two decades, 
translational stroke research focused on neuroprotective approaches in the acute phase after 
stroke, but all compounds reaching the clinical trials did not show any improvement in the patient 
(O'Collins et al., 2006). Therefore, novel treatment strategies for delayed pathophysiological 
events (such as inflammation) need to be further explored. 
 
1.2 Inflammation after stroke 
Within the early period after cerebral blood flow impairment, oxygen and glucose levels are 
reduced in the affected brain region. As a result of the energy depletion, membrane potential is 
lost and neurons and glial cells depolarize triggering a complex pathogenic cascade of 
biochemical events inducing excitotoxicity, peri-infarct depolarizations, inflammation, and 
apoptosis (Fig.1) (Dirnagl et al., 1999).  
In the core of the lesion, cerebral blood flow is reduced 20% and cells are instantly killed. While, 
on the one hand, the core tissue is irreversibly lost, the perilesional tissue at risk (located around 
the surrounding core tissue) is of particular interest as this tissue could be rescued from 
subsequent deterioration with appropriate therapy (Dirnagl et al., 1999). Excitotoxicity not only 
induces acute cell death (necrosis), it can also lead to a more delayed cell death (apoptosis). 
Although in the core of the region, cells depolarized and never repolarized again, in the 
perilesional tissue cells can repolarize investing a high amount of energy. Different peri-infarct 
depolarizations can occur after the lesion, increasing the initial infarct size (Strong et al., 2007).  
This necrotic tissue from the lesion core prompts a robust inflammatory response with the release 
of damage-associated molecular patterns (Iadecola and Anrather, 2011a), which, in turn, can 
activate astrocytes and the local immune cells like microglia. Moreover, proinflammatory 
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mediators such as cytokines and chemokines released from tissue-resident cells as well as the 
induction of transcription factors, prompt the expression of adhesion molecules on the endothelial 
cell surface and participate in the recruitment of peripheral leukocytes to the injury site 
(Gelderblom et al., 2009). In fact, in the last decades several experimental stroke studies focused 
on inflammatory mechanisms after stroke due to their contribution to secondary brain damage 
(Dirnagl, 2004; Liesz et al., 2009) and a possible focus for a therapeutic intervention (Dirnagl et 
al., 1999; Gelderblom et al., 2009). 
 
 
 
Figure 1. Cascade of damaging events in focal cerebral ischemia. The x-axis reflects the evolution of 
cascades over time, the y-axis shows the impact of each element of the cascade on final outcome. 
Schematic picture of the brain shows the extent of core (yellow) and penumbra (red) as it would be seen 
histologically or on imaging studies. Figure adapted from Dirnagl U et al., 1999. 
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In several experimental stroke studies, circulating leukocyte recruitment to the injured brain has 
been associated with an expansion of the infarct lesion. Indeed, leukocyte invasion after a stroke 
is a critical component of the neuroinflammatory response leading to secondary expansion of the 
brain damage (Chamorro et al., 2012; Wang et al., 2007). Consequently, some studies sought to 
block the migration of leukocytes into the ischemic brain and showed a reduction of the infarct 
volume in different stroke models (Liesz et al., 2011; Llovera et al., 2015). Although new 
contributions to the understanding of the role of immune cells after stroke have been done, the 
mechanisms of leukocyte migration of the injured brain are still incompletely understood. 
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1.3 Immune cell migration routes into the brain after stroke 
The central nervous system (CNS) has an immune-privileged environment; it is tightly protected 
from the fluctuating milieu of the bloodstream by the blood-brain barrier (BBB), which is formed 
by brain endothelial cells (BECs) and the blood-cerebrospinal fluid barrier (BCSFB) composed 
of the choroid plexus (ChP) epithelial cells (Redzic, 2011). There are two essential roles of these 
barriers: 1.) Prevention of free diffusion between brain fluids and blood and 2.) Maintenance of 
brain homeostasis via transport of crucial nutrients, ions, and waste products (Ransohoff et al., 
2003; Takeshita and Ransohoff, 2012). 
 
1.3.1 Blood-Brain Barrier 
The blood-brain barrier (BBB) is formed by microvascular endothelial cells, which are 
surrounded by basement membranes, pericytes, and astrocytes. Astrocytic endfeet processes form 
the glia limitans, which, along with its basement membrane and the endothelial basement 
membrane, forms the perivascular space (Man et al., 2007). Moreover, tight junction proteins 
connect the endothelial cell layer and its basement membrane, forming a tight seal to avoid 
diffusion of solutes into the brain (Abbott et al., 2010). Therefore, under physiological 
conditions, the vascular system acts as a barrier that prevents the access of molecules into the 
brain and limits leukocyte access to the CNS. Acute brain injuries and other CNS pathologies 
lead to the common pathophysiological mechanisms of secondary neuroinflammation and 
dysfunctional BBB integrity (Choi and Kim, 2008; Stamatovic et al., 2008). After an ischemic 
stroke, several groups of molecules initiate leukocyte recruitment across the vascular endothelial 
barrier into the central nervous system (CNS). Once leukocytic P-selectin glycoprotein ligand 1 
(PSGL-1) and very late antigen-4 (VLA-4) bind to the endothelial P-selectin and vascular cell 
adhesion molecule-1 (VCAM-1), it allows leukocytes to adhere to endothelial cells. Leukocytes 
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can then migrate to the brain parenchyma across the endothelial cell via the paracellular or 
transcellular pathway (Engelhardt and Ransohoff, 2005; Engelhardt and Sorokin, 2009; 
Laschinger and Engelhardt, 2000; Takeshita and Ransohoff, 2012). 
 
Natalizumab, an effective therapy for multiple sclerosis patients, has been shown to reduce 
lymphocyte invasion into the brain by blocking the α-chain of VLA-4 (anti-CD49d 
antibodies)(Polman et al., 2006; Rice et al., 2005; Steinman, 2005; Yednock et al., 1992). 
Consequently, anti-CD49 antibodies have been investigated in the stroke field to reduce 
leukocyte infiltration into the brain after stroke. Inhibition of the cerebral lymphocyte infiltration 
resulted in a reduction of the infarct volume and improved the behavior outcome after ischemic 
stroke (Liesz et al., 2009; Liesz et al., 2011). Despite this promising new approach, more research 
is needed to be able to translate these findings into a clinical setting. 
 
1.3.2 Blood-Cerebrospinal Fluid Barrier 
The blood-cerebrospinal fluid barrier (BCSFB) is formed by the epithelial cells of the choroid 
plexus (ChP) interconnected by tight junctions. The ChP is localized in the brain ventricles, 
which is filled with cerebrospinal fluid (CSF). Apart from CSF production, BCSFB’s primary 
function is to restrict immune cell and molecule entrance into the brain. Moreover, the ChP is 
responsible for brain homeostasis and plays a critical role as a filtration system via removal of 
metabolic waste from the brain (Bennett et al., 2003; Mortazavi et al., 2014; Wilson et al., 2010). 
The ChP is formed by a cuboidal epithelium surrounding the capillaries and loose connective 
tissue. While the epithelial layer has tight junctions that prevent substances from crossing into the 
CSF, ChP capillaries are fenestrated and are permeable to molecules and immune cells 
(Deczkowska et al., 2016; Shechter et al., 2013a; Ueno et al., 2016). The ChP stroma is home to a 
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diverse number of immune cells, including CD4
+
 T cells, macrophages, and dendritic cells, thus 
serving as a possible port for these immune cells to first enter the brain parenchyma (Kunis et al., 
2013; Meeker et al., 2012; Ransohoff and Engelhardt, 2012). After a CNS injury, the ChP rapidly 
responds to pro-inflammatory mediators released from injured brain parenchyma or invading 
inflammatory cells via the upregulation of adhesion molecules and chemokine expression that are 
essential for lymphocyte trafficking (Ghersi-Egea et al., 2018; Shechter et al., 2013b; 
Szmydynger-Chodobska et al., 2012) (Fig.2). Therefore, ChP epithelial cells play a substantial 
role in controlling the leukocyte entrance into the brain. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.The Central Nervous System (CNS) barriers. The blood–brain barrier (BBB) consists of a 
layer of endothelial cells (interconnected by tight junctions) and glia limitans (a surface made of astrocyte 
endfeet processes). The blood–CSF barrier (BCSFB) at the choroid plexus (ChP) is a structure located in 
brain ventricles and comprises an endothelial wall of fenestrated blood capillaries and a monolayer of tight 
junction-connected epithelial cells. Figure adapted from Deczkowska et al., 2016. 
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Current research studies investigating immune-targeted therapies against post-stroke cellular 
neuroinflammation assume that the BBB is the main leukocyte infiltration route after a stroke 
(Enzmann et al., 2013; Lopes Pinheiro et al., 2016; Zhou et al., 2013). However, recent studies in 
primary neuroinflammatory diseases, such as experimental autoimmune encephalitis (EAE), have 
reported that leukocytes can migrate into the brain through alternative pathways, such as the 
BCSFB (Bennett et al., 2003; Kunis et al., 2015; Mony et al., 2014; Wilson et al., 2010). This 
alternative leukocyte invasion route is yet to be analyzed in post-stroke neuroinflammation. 
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1.4 Obstacles in translational research 
Recently, new experimental studies have been increased to test alternative therapies to improve 
ischemic stroke outcomes such as postischemia, excitotoxic neural damage, depolarization 
spread, and apoptosis or inflammation (Iadecola and Anrather, 2011b; O'Collins et al., 2006). 
Unfortunately, at this time, none of the drugs that showed promise in stroke animal models have 
been translated into clinical use for patients (Moskowitz, 2010; Zivin et al., 1985).  
The availability of reliable preclinical data is essential for selecting drug candidates with high 
clinical potential and consequently for designing the most effective clinical studies. Academic 
and industrial researchers agree on the existence of a “reproducibility crisis”: the results of 
preclinical studies in many research fields (including stroke) lack robustness, and only a small 
fraction of these studies can be replicated (McNutt, 2014). Therefore, international consortia, the 
EU-funded Multi-PART consortium for stroke research and the NIH consortium for preclinical 
assessment of cardioprotective therapies (CAESAR), have attempted to establish guidelines to 
overcome the limitations and low reproducibility of clinical trials of promising preclinical 
treatments to the clinic. Moreover, multicenter preclinical randomized controlled trials (pRCTs) 
were proposed as a promising tool to overcome the current limitations of preclinical in vivo 
studies (Bath et al., 2009; Dirnagl et al., 2013; Lefer and Bolli, 2011).  
Replicating an experiment from one laboratory to another one should be relatively easy when 
using the same protocol and materials, however, Phil Bourne and colleagues (Garijo et al., 2013) 
could conclude that an inexperienced researcher would need an average of 280h to reproduce a 
published method. If then, we also add how complex and sensitive can be surgical protocols, 
probably this time would be even higher. Therefore, one could question the reliability of the 
already published preclinical studies (McNutt 2014). For sure not all failures are due to the lack 
of reproducibility (Tymianski, 2015), preclinical trials also cover other complex steps and each of 
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them provides an opportunity to fail (Editorial, 2013). We could agree that the reproducibility of 
preclinical trials will improve the translation from bench to bedside, but also study design has to 
be important. Some groups reported difficulties associated with translational studies (Bath et al., 
2009; Dirnagl and Fisher, 2012; Ioannidis, 2005; Ioannidis et al., 2014), such as insufficient 
power in most of the studies or missing cross-validation of data by independent study centers 
(Crossley et al., 2008; Dirnagl and Fisher, 2012; Dirnagl et al., 2013; Howells et al., 2014; 
O'Collins et al., 2006). 
Therefore, to solve the current crisis in translational research and contribute to bridge the gap 
between preclinical and clinical research, diverse issues must be undertaken. Single-center 
studies have weaknesses such as low validity, inadequate sample size or low confidence and 
multicenter pRCTs are designed to overcome these issues. In order to improve the validity of 
preclinical research, pRCTs control several elements that clinical RCTs utilize, including a 
randomization, blinded study design or analysis of data by an independent study center. 
Importantly, in contrast to most preclinical single-center trials, pRCT is a confirmatory study 
(Kimmelman et al., 2014).  
 
 
 
 
 
 
 
 
Figure 3. Preclinical randomized controlled trials (pRCTs) can serve as a link in the translational 
research. Preclinical research is mainly exploratory from basic research to single-center drug efficacy 
trials. In contrast, clinical trials are confirmatory studies with the goal of drug approval and establishing 
clinical use. A pRCT adopts elements from preclinical and clinical study design and might be able to 
better predict clinical drug efficacy. Figure adapted from Llovera et al., 2016. 
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To sum up, pRCT studies can provide a large number of samples, a single standardized protocol 
and it is performed by different research centers, thus pRCT studies must be capable helping to 
fill the gap in between preclinical single center research trial studies and human Phase I studies 
clinical trials (Fig. 3). pRCTs may not be the definitive solution, even though they address 
diverse key aspects that have been identified as hidden in the reproduction crisis in preclinical 
research. Therefore, in response to the growing reproducibility crisis in translational medicine, 
pRCT has been developed as a novel research tool.  
Consequently, the first clinical trials have been initiated to test three drugs that are currently 
approved for multiple sclerosis: 1) Fingolimod (FTY720), 2) Enlimomab (anti-ICAM-1 
antibody), and 3) Natalizumab (humanized anti-4-integrin IgG4). Although Fingolimod studies 
showed promising results with a reduction of infarct volume (Fu et al., 2014; Zhu et al., 2015), 
Natalizumab and Enlimomab studies failed to improve the clinical outcome in stroke patients 
(Elkins, 2016; Investigators, 2001). 
 
  
 
 
 
 
 
 
  
Introduction 
 
22 
 
1.5 Research project and conclusions 
As described above, pRCTs may shed some light on how to build a bridge to connect preclinical 
research and clinical trials. Therefore, the first aim of this thesis was to demonstrate the 
feasibility and usefulness of preclinical multicenter trials and to test the efficacy of an anti-
inflammatory therapeutic intervention (blocking leukocyte migration with anti-CD49d 
antibodies) in two experimental stroke models. As described previously, most immune-targeted 
stroke therapies are focused on the endothelium and BBB, but it is still unclear how exactly 
leukocytes migrate to the brain. For this reason, the second aim of this thesis was to investigate 
the BCSFB as an alternative leukocyte cerebral invasion route, which has an essential role in 
primary inflammatory brain diseases (such as EAE), but to date, BCSFB’s role has not been 
investigated after stroke.  
 
To investigate the first aim of the thesis, we used antibodies (anti-CD49) against the α chain of 
the integrin, very late antigen-4 (VLA-4), to block leukocyte transendothelial migration to the 
brain. Anti-CD49d antibodies demonstrated high efficacy in different models of autoimmune 
diseases, and the humanized antibody Natalizumab is one of the most effective therapies for 
multiple sclerosis patients. Moreover, pRCT studies were proposed to increase the robustness of 
novel therapeutic approaches for clinical translation. For this study, we used two different stroke 
models and a total of 315 male C57BL/6J mice from six independent European research centers. 
Among all of the results, we found differences between the results from two ischemic stroke 
models concerning cerebral leukocyte invasion and the efficacy of anti-CD49d treatment. Anti-
CD49d treatment could reduce only 30% of the leukocyte infiltration into the brain parenchyma 
in the permanent distal middle artery occlusion (cMCAO) model, conferring a neuroprotective 
benefit. Besides, different stroke models have different infiltration patterns. Whereas the cMCAO 
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model has an increase of leukocyte infiltration localized in the peri-infarct cortex, the transient 
middle cerebral artery occlusion (fMCAO) model has a lower leukocyte infiltration number 
without a defined localization in the injured hemisphere.  
Apart from the feasibility and usefulness of preclinical multicenter trials, we can describe several 
points of potential improvement for future pRCTs. An obvious limitation of our analysis strategy 
was the constraint to a per-protocol analysis and the lack of an additional intention-to-treat 
analysis. 
 
For the second aim of this thesis, we attempted to comprehend how leukocytes migrate into the 
brain after an ischemic stroke as this mechanism is still unclear. We could observe that T cells 
were predominantly clustered in the peri-infarct cortex and were the most abundant population in 
the ChP five days after the stroke. A series of experiments revealed that T cells were able to 
invade the brain parenchyma from the ChP stroma, thus avoiding entry into the CSF via the tight 
BCSFB. T cells were localized along the proposed invasion route from the ChP stroma to the 
medial-lateral ventricle wall, to the apical corpus callosum (CC), and along the CC to the peri-
ischemic infarct. Furthermore, we could identify that about two-thirds of the infiltrated T cells 
used the ChP of the ipsilateral ventricle while only one-third used other pathways. Moreover, 
CSF pathway blockage caused by matrigel injection into the ipsilateral ventricle after cortical 
stroke did not alter T cell counts in the peri-ischemic region. Altogether, these findings indicate 
ChP is not only an alternative invasion route but also a key invasion route for T cells into the 
brain parenchyma after a stroke. Furthermore, previous reports have demonstrated that larger 
infarcts (fMCAO) induce lower T cell infiltration into the brain parenchyma compared to the 
cortical infarcts (cMCAO). In fact, we could show that in the fMCAO model, the ChP function is 
affected, resulting in a reduction of T cell invasion. Moreover, we could detect a significant 
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decrease in the total cerebral T cells in mice that received a localized photothrombotic (PT) lesion 
of the ipsilateral ChP. These approaches targeting the ChP function validated the crucial role of 
the ChP in the ischemic brain’s T cell migration. 
Altogether, in our first pRCT study, anti-CD49d antibodies could block only 30% of the 
leukocyte infiltration through the BBB endothelium. Moreover, in our second study, we detected 
that two-thirds of the T cells migrate to the peri-ischemic region through the ipsilateral ChP. 
While BBB expresses anti-CD49d in their endothelial cells, BCSFB expresses anti-CD49 in their 
epithelial cells (Steffen et al., 1996). Therefore, CD49d plays a minor role at the ChP, which 
means that stromal lymphocytes in the ChP could not be blocked by anti-CD49d, which is able to 
infiltrate the peri-infarct lesion. Consequently, these data serve as an explanation for the 
discrepant post-stroke T cell infiltration findings.  
In conclusion, we identified ChP as a principal alternative leukocyte migration route into the 
brain after ischemic stroke. Moreover, the first preclinical randomized controlled multicenter trial 
(pRCT) was successfully performed, and we could define several points of potential 
improvement for future pRCTs. Therefore, ChP has to be considered in future translational and 
clinical studies that investigate therapies targeted at post-stroke leukocyte infiltration. 
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2. Summary 
Ischemic stroke affects a large number of people all over the world. The current treatment for 
ischemic stroke, recombinant tissue plasminogen activator (rtPA), is not eligible for all ischemic 
stroke patients due to its short administration time window and contraindications such as 
hemorrhage or oral anticoagulation. Although new and different treatments approaches have been 
reported to provide positive outcomes in experimental stroke models, all failed in clinical trials. 
To overcome the translational research limitations of most biomedical fields, international 
consortia have attempted to establish guidelines for study design and reporting the resultant data. 
Moreover, multicenter preclinical randomized controlled trials (pRCTs) have been proposed as 
tools for “bridging the gap” between experimental research and clinical trials. On the other hand, 
it is known that after a stroke, proinflammatory mediators are released from the peri-infarcted 
tissue, and this leads to the recruitment of leukocytes to the lesion and increases the infarct size. 
Therefore, some studies aimed to block leukocyte migration into the ischemic brain. 
The first aim of the thesis was to confirm some preclinical results and test the viability of 
performing a pRCT. To achieve this, six independent European research centers were involved in 
a project to test the efficacy of anti-CD49d antibodies, which inhibit the migration of leukocytes 
into the brain, in two distinct mouse models of stroke. Pooled results from all centers showed a 
significant reduction of both leukocyte brain infiltration and infarct volume only after the 
permanent distal occlusion of the middle cerebral artery, which causes small cortical lesions. This 
study confirmed that blocking brain leukocyte invasion is an important therapeutic option. 
Moreover, this study supports the feasibility of performing pRCTs. 
Although we had successful results in our previous study, it is still not clear how leukocytes 
infiltrate the brain after stroke. Previous research studies have been focused on the BBB 
vasculature as the main leukocyte invasion of the brain after stroke. On the other hand, alternative 
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leukocyte brain migration routes, such as the blood-leptomeningeal barrier (BLMB) or the blood-
cerebrospinal fluid barrier (BCSFB), were described in other neuroinflammatory diseases, but not 
after stroke.  
Therefore, the second aim of the thesis was to investigate the role of the choroid plexus (ChP) as 
a possible infiltration route of leukocytes after an ischemic stroke. Indeed, we reported an 
accumulation of T cells in the peri-infarcted region, as well as the presence of T cells in the 
ipsilateral ChP in mice and humans after stroke. In vivo cell tracking of photoactivated T cells 
confirmed the migration of T cells from the ChP to the peri-infarcted cortex. The 
photothrombotic lesion of the ipsilateral ChP induces a reduction of T cell invasion into the 
ischemic brain. Moreover, a CCR2-ligand gradient was detected as a potential driving force for 
the T cell intracerebral migration. To sum up, our study showed that ChP is a key invasion route 
for post-stroke cerebral T cell invasion. 
Taken altogether, future stroke therapy studies may consider planning a proper pRCT study 
before performing a clinical trial. Moreover, the ChP has to be under consideration as a potential 
relevant pathway for future therapies for inhibiting leukocyte invasion after stroke. 
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3. Zusammenfassung 
Ischämischer Schlaganfall betrifft eine große Anzahl von Menschen auf der ganzen Welt. Die 
derzeitige Behandlung des ischämischen Schlaganfalls mit rekombinantem gewebespezifischem 
Plasminogenaktivator (rtPA) ist nur für einen geringen Teil der Schlaganfallpatienten geeignet, 
da die Anwendung durch zahlreiche Kontraindikationen einschränkt wird. Obwohl verschiedene 
neue Behandlungsansätze ein positives Ergebnis in experimentellen Schlaganfallmodellen zeigen, 
scheiterten diese bisher alle in klinischen Studien. Um die Grenzen der translationalen Forschung 
im biomedizinischen Bereichen zu überwinden, haben internationale Konsortien versucht, 
Richtlinien für das Studiendesign und für die Berichterstattung der daraus resultierenden Daten 
zu erstellen. Darüber hinaus wurden multizentrische, präklinische, randomisierte kontrollierte 
Studien (pRCTs) als geeignetes Instrument vorgeschlagen, um zwischen experimenteller 
Forschung und klinischen Studien eine Brücke zu schlagen. 
Auf der anderen Seite ist bekannt, dass nach einem Schlaganfall entzündungsfördernde 
Mediatoren aus dem Peri-Infarktgewebe freigesetzt werden. Dies führt zur Rekrutierung von 
Leukozyten in das geschädigte Gehirn und zu einer sekundären Infarktexpansion. Daher zielen 
mehrere aktuelle Studien darauf ab, die Einwanderung von Leukozyten in das ischämische 
Gehirn zu blockieren. 
Das erste Ziel dieser Arbeit bestand darin, präklinische Ergebnisse zu bestätigen und die 
Realisierbarkeit einer pRCT zu testen. Um dies zu erreichen, waren sechs unabhängige 
europäische Forschungszentren involviert, um die Wirksamkeit von CD49d-spezifischen 
Antikörpern, welche die Migration von Leukozyten in das Gehirn hemmen, in zwei 
verschiedenen Maus-Schlaganfallmodellen zu testen. Die zusammengefassten Ergebnisse aus den 
Zentren zeigten eine signifikante Verringerung sowohl der ins Hirn einwandernden Leukozyten 
als auch des Infarktvolumens. Diese Studie bestätigte, dass das Blockieren der Invasion von 
Zusammenfassung 
 
28 
 
Leukozyten eine mögliche therapeutische Option für Schlaganfall-Patienten darstellen könnte. 
Darüber hinaus zeigte diese Studie die Machbarkeit solcher pRCTs als neuartiges Studiendesign 
auf. 
Trotz unserer vielversprechenden Ergebnisse in unserer früheren Studie ist es noch nicht klar, wie 
Leukozyten nach Schlaganfall ins Gehirn infiltrieren. Frühere Forschungsstudien konzentrierten 
sich auf zerebrale Kapillaren als Hauptinvasionsroute für Leukozyten in das Gehirn nach einem 
Schlaganfall. Auf der anderen Seite wurden alternative Invasionsrouten, wie die leptomeningeale 
Blut-Hirn-Schranke oder die Blut-Liquor-Schranke bei neuroinflammatorischen Erkrankungen 
beschrieben, jedoch nicht nach einem Schlaganfall. 
Der zweite Teil der Arbeit beschäftigte sich daher mit der Rolle des Choroid plexus (ChP) als 
mögliche Einwanderungsroute von Leukozyten nach ischämischen Schlaganfall. Wir konnten in 
diesem Teil der Arbeit tatsächlich eine Akkumulation von T-Zellen in der Peri-Infarktregion 
sowie das Vorhandensein von T-Zellen im ipsilateralen ChP bei Mäusen und Menschen nach 
einem Schlaganfall feststellen. Die Analyse von in vivo photoaktivierten T-Zellen im 
Seitenventrikel bestätigte die Migration von T-Zellen vom ChP in den schlaganfallnahen Cortex. 
Eine photothrombotische Läsion des ipsilateralen ChP induzierte eine Reduktion der T-Zell-
Invasion in das ischämische Gehirn. Darüber hinaus wurde ein CCL2-Gradient als potentieller 
Mechanismus für die intrazerebrale, gerichtete Migration von T-Zellen nachgewiesen. 
Zusammenfassend zeigte unsere Studie, dass der ChP eine Hauptinvasionsroute für die zerebrale 
T-Zellinvasion nach Schlaganfall ist. 
Abschließend betrachtet sollten zukünftige Schlaganfall-Therapiestudien die Planung einer 
geeigneten pRCT-Studie erwägen, bevor eine klinische Studie durchgeführt wird. Darüber hinaus 
muss der ChP als ein relevanter Weg für zukünftige Therapien zur Hemmung der Invasion der 
Leukozyten nach Schlaganfall berücksichtigt werden. 
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detected a gradient of CCR2 ligands as the potential driving 
force and characterized the neuroanatomical pathway for the 
intracerebral migration. In summary, our study demonstrates 
that the ChP is a key invasion route for post-stroke cere-
bral T-cell invasion and describes a CCR2-ligand gradient 
between cortex and ChP as the potential driving mechanism 
for this invasion route.
Introduction
Ischemic stroke remains one of the main causes of death and 
disability in the world with only very limited therapeutic 
options [10]. Over the past decade, post-ischemic neuro-
inflammation in secondary neuronal loss and repair after 
stroke has come into the focus of preclinical stroke research 
[14, 25]. Invasion of circulating, pro-inflammatory lympho-
cytes has been described as the key mechanism of the post-
ischemic neuroinflammatory response, which aggravates the 
Abstract Neuroinflammation contributes substantially to 
stroke pathophysiology. Cerebral invasion of peripheral leu-
kocytes—particularly T cells—has been shown to be a key 
event promoting inflammatory tissue damage after stroke. 
While previous research has focused on the vascular inva-
sion of T cells into the ischemic brain, the choroid plexus 
(ChP) as an alternative cerebral T-cell invasion route after 
stroke has not been investigated. We here report specific 
accumulation of T cells in the peri-infarct cortex and detec-
tion of T cells as the predominant population in the ipsilat-
eral ChP in mice as well as in human post-stroke autopsy 
samples. T-cell migration from the ChP to the peri-infarct 
cortex was confirmed by in vivo cell tracking of photoacti-
vated T cells. In turn, significantly less T cells invaded the 
ischemic brain after photothrombotic lesion of the ipsilateral 
ChP and in a stroke model encompassing ChP ischemia. We 
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initial infarct volume and exacerbates stroke outcome [4, 24]. 
Recent experimental studies demonstrated that amelioration 
of cerebral lymphocyte invasion by reducing the number 
of circulating lymphocytes in different experimental stroke 
models improved functional outcome [1, 18, 26, 31]. In par-
allel, first clinical trials have been initiated which tested this 
treatment approach in stroke patients using two drugs cur-
rently approved for multiple sclerosis, fingolimod (FTY720) 
and natalizumab (humanized anti-α4-integrin IgG4). Even 
though the early translation of immune-targeted therapies 
in stroke and the first positive results are very promising, 
these attempts have also been criticized as premature in 
face of several unsolved key questions in the field of stroke 
immunology [9, 39]. One of these main unresolved questions 
in the field is the exact mechanism of lymphocyte migra-
tion into the ischemic brain. In stroke research, the vascular 
migration route across the (damaged) blood–brain barrier 
(BBB) has been assumed as the main invasion route for cir-
culating lymphocytes into the ischemic brain [41]. Although 
other infiltration routes such as meningeal blood vessels or 
the choroid plexus (ChP) have previously been characterized 
as important entry sites of lymphocytes in primary inflam-
matory brain disorders such as experimental autoimmune 
encephalitis (EAE) [30, 45], these alternative invasion sites 
have not been analyzed in post-stroke neuroinflammation.
Therefore, in the present study, we aimed to investigate 
the role of the ChP as a potential infiltration route for lym-
phocytes—particularly pro-inflammatory T cells—into the 
post-ischemic brain. We particularly focused on the ChP as 
an infiltration route for T cell due to the key pathophysi-
ological role of T cells in post-stroke neuroinflammation 
and a specific invasion pattern observed for T cells in con-
trast to myeloid cells. We observed that a large proportion of 
brain-invading T cells migrate through the ChP after stroke. 
Moreover, we could identify the CCR2-dependent pathway 
as a key chemoattractant signal for T cells along the choroi-
dal infiltration route.
Materials and methods
Mice
All experiments were conducted in accordance with national 
guidelines for the use of experimental animals, and all pro-
tocols were approved by the German governmental com-
mittees (Regierung von Oberbayern, Munich, Germany). 
83 wild-type male C57BL6/J mice were obtained from 
Charles River. 17 Rag1−/− (B6.129S7-Rag1tm1Mom/J), 10 
CAG-EGFP (C57BL/6-Tg (CAG-EGFP)131osb/LeySopJ), 
22 heterozygous PA-UBC-GFP (B6.Cg-Ptprc Tg (UBC-
PA-GFP)1Mnz/J), 5 CCL2-RFP (B6.Cg-Ccl2tm1.1Pame/J) 
and 5 CCL2−/− (B6.129S4-Ccl2tm1Rol/J) male mice were 
obtained from Jackson Laboratories (USA). Eight female 
LysM-eGFP (Lyz2tm1.1Graf) mice were kindly donated 
by M.Sperandio (Walter BrendlCenter for Experimental 
Research, Munich, Germany).  CCR2RFP/RFPCX3CR1GFP/+ 
and  CCR2RFP/+CX3CR1GFP/+ mice were originally gener-
ated by Israel Charo and Richard Ransohoff [32] and bred 
at the Theodor Kocher Institute, University of Bern, Swit-
zerland. All other animals were housed at the core animal 
facility of the Institute for Stroke and Dementia Research, 
Munich, under controlled temperature (22 ± 2 °C), with 
a 12-h light–dark cycle period and had access to pelleted 
food and water ad libitum. All animals used for this study 
were at 8–12 weeks of age, expect for the aged mice which 
were 8 months old. Number of excluded animals from each 
experiment is shown in Suppl. Table 1.
Human samples
Both lateral ventricles with surrounding brain tissue from 
five stroke and six control human patients were obtained 
from the Human Brain and Spinal Fluid Resource Center 
(HBSFRC) Los Angeles, USA. Patient characteristics are 
described in Suppl. Table 2. Samples were sent frozen to our 
facility where they were kept at −80 °C until used. Samples 
were slowly defrosted at 4 °C for 3 h and then fixed in 4% 
paraformaldehyde (PFA) (pH 7.4) for 1 h at 4 °C and after-
wards at room temperature (RT) for 48 h in the dark. After 
parafinization, 5 µm thick sections were cut for histology and 
immunohistochemistry. For conventional histological inves-
tigations, hematoxylin–eosin (H&E) stains were performed. 
Immunohistochemistry for CD3 (rabbit polyclonal, A0452/
DAKO, diluted 1:50) or CD68 (mouse clone KP1, M0814/
DAKO, diluted 1:50) was done in a Ventana Benchmark GX 
using the i-View detection system and diaminobenzidine as 
chromogen following the instructions of the manufacturer. 
Counterstaining was done with hematoxylin. ChP samples 
were analyzed under a microscope (Axio ImagerM2, Zeiss) 
and each CD3- and CD68-positive cell was counted. Total 
cell count per staining and per sample was normalized to the 
ChP area which was manually determined on H&E-stained 
sections.
Human RNA samples from six patients were obtained 
from the Hospital de la Vall d´Hebron, Barcelona. Patient 
characteristics are described in Suppl. Table 3. RNA from 
the ipsilateral and contralateral cortex of each patient 
was isolated using the Speed tools total RNA extraction 
kit (21.211, Biotools). 20 µl of total RNA was hybrid-
ized with reporter and capture probes in human nCounter 
gene expression code sets GX Human Immunology Kit V2 
(XT-SC-HIM2-12) according to manufacturer’s instruc-
tion (NanoString Technologies). Data were analyzed using 
nSolver Analysis software. Additional analysis was per-
formed using “NanoStringNorm” in R (version 3.3.1) [43]. 
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The geometric mean was used to summarize the CodeCount 
(positive) and SampleContent (housekeeping genes) con-
trols, thus minimizing the impact of outliers. Stringent back-
ground correction was applied (mean + 2 standard devia-
tions) to minimize false positives and therefore increasing 
specificity. As an additional QC step, housekeeping genes 
with high variability (SD >2) were removed before normal-
izing the data.
Permanent middle cerebral artery occlusion (pMCAo) 
model
As previously described [21], animals were anesthetized 
with volatile anesthesia (isoflurane in 30%O2/70%N2O) and 
placed in lateral position. After a skin incision between eye 
and ear, the temporal muscle was removed and the MCA 
identified. Then, a burr hole was drilled over the MCA and 
the dura mater was removed. The MCA was permanently 
occluded using bipolar electrocoagulation forceps. Perma-
nent occlusion of the MCA was visually verified before 
suturing the wound. During the surgery, body temperature 
was maintained using a feedback-controlled heating pad. 
Mice that developed a subarachnoid hemorrhage during 
surgery were excluded from the analysis.
Transient middle cerebral artery occlusion (fMCAo) 
model
Animals were anesthetized (isoflurane in 30%O2/70%N2O, 
local lidocaine) and received an incision between ear and 
eye to expose the temporal skull. A laser Doppler probe was 
placed over on the skull above the MCA territory. Animals 
were then placed in supine position. After a midline neck 
incision, the common carotid artery and left external carotid 
artery were isolated and ligated, a 5 mm silicon-coated fila-
ment (Doccol, #7019PK5Re) was inserted into the internal 
carotid artery and MCA occlusion checked by a correspond-
ing laser Doppler flow reduction. After 90-min MCAo, ani-
mals were anesthetized again and the filament was removed. 
For the survival period, animals were kept in their home 
cage with facilitated access to water and food. Mice without 
a reduction in blood flow to <20% of the baseline, controlled 
by a laser Doppler flow, were excluded from the analysis.
Photothrombosis (cortical and choroid plexus lesion)
Animals were placed in a stereotactic device under anesthe-
sia (isoflurane in 30%O2/70%N2O).
For ChP lesions, a midline incision was performed to 
expose the skull and both bregma and Lambda points were 
identified. A burr hole was drilled at 3 mm anterior from 
bregma, 1 mm left from midline. Animals then received 
10 µl/g body weight (BW) of 1% Rose Bengal in phosphate 
buffer saline (PBS) intraperitoneally (i.p). and after 5 min 
an optical fiber with an inner diameter of 200 µm and a NA 
of 0.22 was inserted at 4 mm depth from the brain surface 
to reach the left ventricle with an inclination angle of 30°. 
Photothrombosis of the ChP was achieved by 15 min illumi-
nation via the fiber probe at 532 nm wavelength (Luxivision, 
Germany). Control animals received the same treatment with 
saline injection instead of the Rose Bengal administration, 
including illumination of the lateral ventricle.
For cortical lesions, after midline incision and skull expo-
sure, a laser (Cobolt HS-03, Solna, Sweden) was centered at 
4 mm lateral to bregma on the left side. A fiber optic bundle 
of 1.5 mm diameter at the tip was used to obtain a stroke 
lesion similar to that induced by the pMCAo model. Animals 
then received 10 µl/g body weight of 1% Rose Bengal in 
PBS i.p. and after 5 min the brain was illuminated through 
the intact skull for 15 min at constant 561 nm wavelength.
Traumatic brain injury
Traumatic brain injury (TBI) was induced as previously 
described [34]. Briefly, mice were anesthetized with a gas 
mixture containing 2% isoflurane, 65%  N2O, and 33%  O2. A 
craniotomy window was drilled over the right parietal cortex 
under continuous cooling with saline. A cortical contusion 
was produced using a controlled cortical impact device opti-
mized for use in mice (cylinder diameter 3.0 mm; velocity 
6.0 m/s; penetration depth 0.5 mm; contact time 150 ms). 
Immediately following the impact, the bone flap was reim-
planted and fixed using histoacrylic glue. The animals were 
then allowed to wake in a recovery chamber (33 °C and 50% 
humidity) and killed 5 days post-injury.
Assessment of infarct volume
Mice were deeply anesthetized 5 days after stroke induc-
tion and transcardially perfused with 10 ml saline. Brains 
were removed, frozen immediately on powdered dry ice and 
stored at −20 °C. For infarct volumetry, brains were seri-
ally sectioned (400 μm intervals, 20 μm thick) and stained 
for cresyl violet (CV) as previously described [21]. CV-
stained sections were scanned at 600 dpi on a flatbed scan-
ner (Canon). For the pMCAo and PT model, direct infarct 
measurement was used after validating the absence of edema 
at the investigated time point (5 days after pMCAo or PT). 
The total infarct volume was measured with ImageJ and 
determined by integrating measured areas and distances 
between sections.
Intraventricular matrigel injection
Immediately after pMCAo, animals were prepared as 
described above for the photothrombosis procedure. 
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Specifically, a 10 µl Hamilton syringe with a 10 mm length 
needle (Hamilton, #7804-03) was introduced into the lat-
eral ventricle at an inclination angle of 30°. For the CSF 
blockage, 6 µl of matrigel (BD Matrigel™ Matrix, BD Bio-
sciences, #354230) was injected over 5 min. Matrigel was 
kept at 12 °C in a cooling block until the time of injection, 
in order to prevent its polymerization. 5 days after pMCAo 
and matrigel injection, mice were transcardially perfused 
with 10 ml saline and 10 ml 4% PFA. For the visualization 
of the matrigel into the ventricle, 5 µl of matrigel + 1 µl of 
Evans Blue was injected in 5 min, 24 h after the injection 
mice were killed, brain was cut and immediately visualized 
under a microscope.
Immunohistology
Mice were transcardially perfused at the indicated time 
points with 10 ml saline and 10 ml 4% PFA (pH 7.4), then 
post‐fixed in 4% PFA for 4 or 24 h for PA-UBC-GFP animals 
at 4 °C and immersed with 30% sucrose in PBS, then brains 
were frozen in −20 °C isopentane. 12 µm thick coronal 
sections were obtained at the level of anterior commissure 
for immunohistochemical analysis. Sections were mounted 
on SuperfrostPlus Slides (Thermo Scientific) and stored at 
−80 °C. Then sections were dried at room temperature for 
1 h. After washing with PBS, slides were fixed with acetone 
at −20 °C for 5 min, this was followed by washing with 
PBS and PBS containing 0.1% Triton and incubation in 
blocking buffer containing 0.1% Triton, 0.05% Tween20, 
1% bovine serum albumin, 0.1% cold fish skin gelatine and 
2% goat serum in PBS at RT for 1 h before overnight incu-
bation at 4 °C with the primary rabbit anti-CD3 antibody 
(1:50, abcam #16669), rat anti-CD4 antibody (clone GK1.5, 
1:200, Abcam), chicken anti-laminin (1:200, Abcam) or 
mouse anti-CD45 (1:100, clone 104-2, Abcam) and labeled 
for 1 h with the secondary antibody AF594 goat anti-rabbit 
(1:200, Invitrogen), Cy3 goat anti-rat IgG + IgM (H + L) 
(1:200, Jackson Immunoresearch), FITC anti-chicken Ig 
H& <l (1:200, Abcam) or AF488 goat anti-mouse IgG 
(H + L) (1:100, Invitrogen). Finally, sections were stained 
with DAPI and mounted with fluoromount medium (Sigma). 
Samples were analyzed on an epifluorescence microscope 
(Zeiss Axiovert 200 M) or a confocal microscope (Zeiss 
880). CD3+ cells were counted on one 12 µm section per 
brain at bregma or on three consecutive 12 µm sections at 
bregma ±60 µm for PA-UBC-GFP animals. The infarct core 
was delimitated on consecutive CV-stained sections for each 
individual animal. Only cells at the outer border of this area 
(peri-infarct region) were included for quantification analy-
sis. The localization of each single  CD3+ and  CD45+ was 
marked on a topographic map according to the mouse brain 
atlas to achieve cumulative localization maps.
For the ChP cell death analysis: 24 h after pMCAo and 
fMCAo, mice were perfused with 10 ml saline and brains 
were removed, placed in cold PBS and the ChP from both 
lateral ventricles were isolated. Apoptotic cell death was 
detected by terminal deoxy-nucleotidyl-transferase-mediated 
dUTP nick-end labeling (TUNEL) according to the manu-
facturer’s instructions (Millipore). 20-µm thick coronal sec-
tions were stained with the TUNEL kit to verify cell death 
in the brain.
Flow cytometry
After perfusion with saline, the ChP was removed under a 
stereomicroscope (Leica) and collected in 200 µl Dulbecco’s 
Modified Eagle Medium (DMEM) + 10% fetal calf serum 
(FCS). ChP cells were isolated by incubating the samples 
in 2  ml of digestion mix [DMEM  +  10% FCS  +  0.4% 
DNASEI (#11284932001, Roche)  +  3% CollagenaseD 
(#11088866001, Roche)], 10 min at 37 °C, and then mechan-
ically dissociated. Brain homogenates of both hemispheres 
were prepared by the same dissociation/digestion protocol. 
Cerebral mononuclear cells were subsequently isolated using 
a 70 and 40% discontinuous Ficoll gradient. The following 
mouse antigen-specific antibodies were purchased from eBi-
oscience: CD45 eF450 (30-F11), CD11b PE-Cy7 (M1/70), 
CD3 V510 or FITC (17A2), CD19 APC-Cy7 (eBisID3), 
CD8 PE (53-6.7), CD4 PerCP5.5 (45-0042-82), Ly6C APC 
(HK1.4), Ly6G PE Cy7 (RB6-8C5) and Ly6G PE (1A8). 
To quantify the various cell populations, cells were stained 
with specific antibodies in accordance with the manufac-
turer’s protocols, acquired in a FACSVerse flow cytometer 
and analyzed with FlowJo software (version 10, Tree Star).
Adoptive T‑cell transfer
Spleen and mesenteric lymph nodes from CAG-eGFP mice 
were isolated under sterile conditions and kept in MACS 
buffer (PBS + 0.5% BSA + 2 mM EDTA). After preparing 
a single cell suspension, T cells were isolated using a mouse 
T-cell enrichment kit (eBioscience). Rag1−/−mice received 
 106 T cells in 500 µl PBS i.p. Stroke induction was per-
formed 7 days after the T-cell transfer to allow expansion of 
T cells in the recipient mice.
Clearing and light‑sheet microscopy
For visualization of the T-cell invasion pattern, mice 
were perfused transcardially with 10 ml saline and 10 ml 
4% PFA (pH 7.4) 5  days after pMCAo induction in 
Rag1−/− mice receiving adoptive (eGFP+) T-cell trans-
fer. For the study of the neuroanatomical structure of 
the ChP of lateral ventricles, mice were perfused with 
lectin-FITC in normal saline. Then mice were perfused 
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transcardially with 10 ml saline and 10 ml 4% PFA (pH 
7.4). Whole brains were cleared using uDISCO protocol 
[28]: first, they were serially incubated in tert-butanol in 
12 h until overnight incubation in 100% tert-butanol. The 
next day, samples were incubated for 1 h and 30 min in 
dichloromethane and finally incubated in refractive index 
matching solution BABB-D15, prepared by mixing BABB 
(benzyl alcohol + benzyl benzoate 1:2) with diphenyl 
ether (DPE) at a ratio of 15:1 and adding 0.4% vol dl-
alpha-tocopherol (Vitamin E), for at least 4 h until the 
samples became transparent. Next, samples were imaged 
by a light-sheet microscope (LaVision BioTec). Images 
were acquired with a z-step of 4–8 µm, using 50 ms as 
exposure time and tiling scans to cover the entire speci-
men. Images obtained by light-sheet microscopy were 
analyzed by Amira software (version 6) for segmentation 
and 3D reconstruction. Due to uneven light penetration 
through the sample, we equalized raw image stacks using 
the pseudo flat-field correction method with the BioVoxxel 
plugin in Fiji software. The infarct core was segmented 
manually for exclusion from further analyses. T cells were 
segmented as individual cells for illustration using a 1.7-
fold ratio of the transcellular fluorescence intensity profile 
peak over the neighboring tissue background fluorescence. 
This threshold was determined using manual identification 
of cells based on size, shape and peak signal intensity. 
No additional autofluorescence correction or background 
subtraction was performed.
In vivo photoactivation
Animals were prepared as described above for the photothrom-
bosis procedure including insertion of an optical fiber into the 
lateral ventricle at an inclination angle of 30°. For the in vivo 
“pulse-chase experiment”: photoactivation was performed for 
5 min with a laser source of 405 nm wavelength (Luxivi-
sion, Germany) with an effective output power at the tip of 
the fiber of 5 mW. For 24-h photoactivation in freely behav-
ing mice: immediately after pMCAo a burr hole was drilled 
under isoflurane anesthesia 3 mm anterior from bregma, 1 mm 
left from midline. Then a mono fiberoptic cannula with an 
inner diameter of 200 µm, a NA of 0.22 and 4 mm length 
was inserted into the left lateral ventricle with an inclination 
angle of 30° and fixed with dental cement (Cyano Veneer, 
Hager Werken). In another set of experiments, photoactiva-
tion was performed 4 days after pMCAo for 24 h at constant 
405 nm illumination. Mice were then transcardially perfused 
with 10 ml saline and 10 ml 4% PFA. PA-GFP+ and PA-
GFP− cells were quantified on coronal sections. Percentage of 
infiltrated T cells shown in Fig. 2h was calculated as follows: 
[(T cells at 5 days − T cells at 4 days)∕total T cells at 5 days] ×
100].
RT‑PCR array
Four 100 µm thick brain cryosections from naïve animals and 
24 h pMCAo animals were collected into a MembraneSlides 
1.0 Pen (Zeiss). Microbeam laser microdissection (Zeiss) was 
used to cut the ChP and peri-infarct cortex (880 µm × 620 µm) 
of the sections. Microdissectioned tissue was carefully placed 
with sterile forceps into a 0.5 ml sterile sample tube. Arcturus-
PicoPure RNA Isolation Kit (Applied Biosystems) was used 
for RNA extraction and  RT2PreAMPcDNA syntesis Kit (Qia-
gen) was used for the cDNA synthesis. Finally, a RT2 Profiler 
PCR Array for chemokines and chemokine receptors (PAMM-
022Z, Qiagen) was run on a Roche LightCycler 480 following 
the manufacturer’s instructions. Data were analyzed with  RT2 
Profiler PCR Array Data analysis software (version3.5) from 
SABiosciences.
Histological CCL2 gradient analysis
24 h after pMCAo induction in CCL2-RFP reporter mice, ani-
mals were prepared as described above for immunohistological 
analyses. A mosaic picture from a 12 µm coronal section at 
bregma level was obtained with a confocal microscope (Zeiss 
880) (40× magnification), producing 346 regions of interest 
(ROI). Mean RFP signal per individual ROI from each individ-
ual z-stack was analyzed by the thresholding technique using 
ImageJ software. Following this, RFP values were rasterized 
from each ROI, and normalized to the range between 1.0 and 
10.0, representing 1.0 the lowest and 10.0 the highest RFP 
expression. Each ipsilateral ROI was subsequently normalized 
to the anatomically homotypical ROI of the contralateral hemi-
sphere to normalize for unspecific background fluorescence.
Statistical analysis
Data were analyzed using GraphPad Prism (version 6.0). Sum-
mary data are expressed as the mean ± standard deviation 
(SD) or mean ± standard error of the mean (SEM). All data 
sets were tested for normality using the Shapiro–Wilk normal-
ity test. The groups containing normally distributed data were 
tested using a two-way Student’s t test (for 2 groups) or ANOVA 
(for >2 groups). The remaining data were analyzed using the 
Mann–Whitney U test. Differences with a p value <0.05 (or <0.1 
for the PCR array) were considered to be statistically significant.
Results
The invasion patterns of myeloid and T cells differ 
after stroke
We investigated the regional distribution pattern of myeloid 
and T cells in a focal, cortical ischemia model in mice by 
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permanent occlusion of the distal middle cerebral artery 
(pMCAo). Cerebral T cells where visualized by immunohis-
tological staining and myeloid cells by LysM-eGFP reporter 
mice. The ischemic core itself was excluded from this and 
any subsequent analyses, as we focused on the role of invad-
ing leukocytes to secondary mechanisms in the surrounding 
tissue at risk rather than the already necrotic infarct tissue, 
which undergoes later liquefaction. 5  days after stroke 
induction—which was the time point of maximum cerebral 
leukocyte invasion in this model (Fig. 1d, e)—we observed 
LysM-eGFP-positive myeloid cells to uniformly surround 
the ischemic core (Fig. 1a). In contrast, analysis of regional 
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T-cell distribution revealed a completely different invasion 
pattern with T cells predominantly clustering in the peri-
infarct cortex between the lateral ventricle and the lesion site 
(Fig. 1b). To better visualize this serendipitous observation 
of a specific T-cell distribution pattern, we performed 3D 
light-sheet microscopy of uDISCO solvent-cleared brains 
[28]. For this analysis, we adoptively transferred eGFP + T 
cells to lymphocyte-deficient Rag1−/− mice. Seven days 
later, we induced the stroke lesion and at 5  days post-
lesion performed clearing and imaging of whole brains by 
light-sheet microscopy. Thereby, we were able to confirm 
3-dimensional T-cell invasion clustering as a “wave front” in 
the peri-infarct cortex between the lateral ventricle and corti-
cal infarct core (Fig. 1c). This obvious difference in the inva-
sion pattern between T cells and myeloid cells prompted us 
to further investigate potential differences in cerebral migra-
tory pathways between leukocyte subsets. We performed a 
quantification of myeloid cells and T-cell counts in the brain 
parenchyma and ChP by flow cytometry. As expected, both 
populations, myeloid cells  (CD45highCD11b+) and T cells 
 (CD3+), were increased in the ipsilateral compared to the 
contralateral hemisphere after stroke. The total cell number 
of myeloid cells was substantially higher than of T cells 
in the parenchyma (Fig. 1f). In contrast to the brain paren-
chyma, cellular distribution of leukocyte subpopulations dif-
fered in the ChP isolated from both lateral ventricles. Flow 
cytometric analysis revealed a surprisingly high absolute cell 
numbers of T cells in the ChP (Fig. 1g), which we were able 
to confirm by histological staining demonstrating accumula-
tion of T cells in the ChP stroma (Fig. 1h). To test whether 
the specific clustering of T cells in the peri-infarct cortex 
is merely a model-dependent effect after pMCAo surger-
ies or a distinct feature attributable to specific mechanisms 
of post-stroke T-cell invasion, we analyzed regional T-cell 
distribution in an independent cortical infarct model. We 
induced photothrombosis (PT) of the cortex through the 
intact skull without any surgical manipulation at the skull 
or intracerebral structures, resulting in ischemic lesions of 
similar shape and location as pMCAo (Suppl. Figure 1). 
Although the infarct volume was smaller in the PT model, 
we detected a comparable cerebral T-cell invasion pattern 
with peri-infarct cortical T-cell clustering and with simi-
lar absolute cell counts per histological section as in the 
pMCAo model. Additionally, we could confirm a similar 
T-cell invasion pattern also in a third independent model 
of cortical injury: mild TBI and finally, also after pMCAo 
in aged animals (Suppl. Figure 1). These results confirmed 
a previously unrecognized and specific invasion pattern of 
T cells after cortical infarction in the different acute brain 
injury models tested. Considering the differences in regional 
invasion patterns and relative abundance in the ChP between 
monocytes and T cells, these results indicated a potentially 
specific role of the ChP for cerebral invasion of T cells after 
stroke.
The choroid plexus is a primary entry site for T cells 
into the ischemic brain
Based on these descriptive results, we next aimed to inves-
tigate specifically the intracerebral migration of T cells 
from the ChP to the peri-ischemic cortex after stroke. To 
this end, we used transgenic UBC-PA-GFP mice express-
ing photoactivatable (PA)-GFP in T cells, in which illu-
mination at 405 nm results in a stable shift in the peak 
excitation wavelength with a half-life of approximately 
30 h [42]. This model enabled us to perform an in vivo 
“pulse-chase experiment” with labeling of T cells within 
one lateral ventricle with high anatomical precision. Four 
days after pMCAo, a 40 µm thin laser fiber was intro-
duced into the ipsilateral ventricle and illuminated at a 
wavelength of 405 nm for 5 min (Fig. 2a), then animals 
were killed at different time points after the illumination 
and histologically analyzed for the localization of GFP-
positive/-negative T cells stained for CD3+ (Fig. 2b). This 
validation of T-cell-specific photoactivation was neces-
sary due to the potential expression of PA-GFP also in 
other hematopoietic cell populations, which was, however, 
not observed in this model. We detected photoactivated T 
cells  (CD3+ PA-GFP+) in the peri-infarct cortex as early 
Fig. 1  Lymphocytes display a distinct cerebral invasion pattern. 
Accumulative topographic representation of each single a myeloid 
cell (inset: green LysM-eGFP+ myeloid cells, blue nuclear DAPI 
stain) and b  CD3+ T cell (inset: red  CD3+ T cell, blue nuclear DAPI 
stain) 5 days after permanent MCA occlusion (pMCAo). Cells were 
accumulated from one section at bregma level of five animals each. 
The infarct is depicted in gray. Scale bar 10 µm. c T-cell segmenta-
tion and 3D reconstruction after brain clearing of 5 days post-lesion 
of transferred eGFP + T cells to lymphocyte-deficient Rag1−/− mice 
revealed specific T-cell distribution (yellow dots) in the peri-infarct 
cortex between the ipsilateral ventricle and the lesion 5  days after 
pMCAo. The dashed line demarcates the infarct core. d Correspond-
ing cumulative topographic maps of CD45+ leukocytes at the indi-
cated time points after stroke. Cells were accumulated from one sec-
tion at bregma level of five animals each. Each cell is represented as 
a single dot. The infarct is depicted in gray. e Quantification of total 
leukocytes at the indicated time points after pMCAo, indicating the 
peak of the infiltrated cells at 5  days after pMCAo. Comparative 
analysis are represented as mean  ±  SD. f Flow cytometric analysis 
showing the absolute number of myeloid cells (CD45+CD11b+) 
and T cells (CD3+) in the ipsilateral ischemic (Ipsi) and contralat-
eral (Contra) brain hemispheres 5  days after pMCAO. g Myeloid 
cells  (CD45high  CD11b+) cells and T cell  (CD3+) ratios in ChP 
5  days after pMCAO were substantially different between the ipsi- 
and contralateral ChP after stroke as well as an increased cellularity 
of the ipsilateral ChP was observed after stroke compared to a naïve 
ChP (n  =  10–18, 3 individual experiments). Data are presented as 
mean ± SEM h left, photograph showing the ChP located in the lat-
eral ventricle 5 days after stroke. Right representative image demon-
strating T-cell (CD4+) accumulation in ChP 5 days after stroke. Scale 
bar 20 µm
◂
 Acta Neuropathol
1 3
as 1 h after illumination and the number of photoacti-
vated T cells peaked and reached a plateau at 8 h after 
intraventricular illumination (Fig. 2c, d). These results 
demonstrate a directed intracerebral migration of T cells 
from the ChP of the ipsilateral ventricle to the peri-infarct 
cortex after stroke. Importantly, as a control experiment, 
we did not observe photoconverted cells in the brain 
parenchyma at the proximity of the ventricle 24 h after 
inducing illumination in the ventricle (Suppl. Figure 3). 
Interestingly, at early time points after intraventricular 
illumination photoactivated T cells were located in the 
corpus callosum while at later time points, GFP-positive T 
cells were mainly detected in the cortex (Fig. 2c, d). This 
shift in the photoactivated T-cell localization suggests an 
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intraparenchymal migration from the lateral ventricle to 
the cortex along the corpus callosum.
Notably, a single 5 min pulse for PA-GFP activation in 
the lateral ventricle resulted in optical labeling of more 
than 50% of T cells detected in the peri-infarct cortex ana-
lyzed at the late time points after photoactivation (8 and 
12 h, Fig. 2c, d). Yet, this experiment was not able to pre-
cisely estimate the proportion of cerebral T cells entering 
via the ChP. Therefore, we performed a similar intraven-
tricular photoactivation experiment starting 4 days after 
stroke induction, however, with prolonged illumination 
over 24 h of freely behaving mice using an optogenetic 
illumination setup and killing the animals directly at the 
end of the illumination period in awake, freely moving 
mice (Fig. 2e, f). We aimed to determine a rough estimate 
for the ratio of invading T cells via the ipsilateral ChP in 
the lateral ventricle or by other invasion routes over this 
24-h period from 4 to 5 days after stroke by subtracting 
the number of T cells detected at 4 days post-lesion (i.e., 
before intraventricular photoactivation, Fig. 2g), which 
was determined in a second set of control-operated ani-
mals without intraventricular illumination. Importantly, 
long-term photoactivation of the lateral ventricle itself did 
not induce an inflammatory reaction compared to mice 
that underwent the same procedure without illumination 
(Suppl. Figure 4). Hereby, we detected by this approxima-
tion that about two-thirds of the T cells infiltrated via the 
ChP of the ipsilateral ventricle while one-third of T cells 
infiltrated along other pathways (Fig. 2g, h), confirming 
that the ChP of the lateral ventricle is the predominant 
invasion route for T cells after cortical infarction.
Choroidal T cells invade the brain parenchyma
The above-shown results obtained in the UBC-PA-GFP 
mouse model suggested infiltration of T cells through 
the ChP and migration to the peri-infarct cortex along 
the corpus callosum. Surprisingly, the neuroanatomical 
structure of the ChP of lateral ventricles in adult mice 
as well as the exact migration pathway of T cells from 
the ChP stroma to the brain parenchyma have previously 
not been well described. Therefore, we performed light-
sheet microscopy of lectin-perfused and cleared brains 
enabling 3-dimensional visualization of choroidal vascu-
larization and its anatomical junction to the ventricle wall. 
In accordance with previous studies on ChP development 
during embryogenesis [23], we detected attachment of the 
ChP to the medial wall of the lateral ventricle (Fig. 3a, b) 
clearly visible by vasculature penetrating from the brain 
parenchyma into the ChP (Suppl. video). 3-dimensional 
reconstruction of segmented ChP, lateral ventricle and 
the corpus callosum revealed the close proximity of these 
anatomical structures (Fig. 3c, d). Therefore, we hypoth-
esized that T cells shall be able to directly invade the brain 
parenchyma from the ChP stroma, avoiding first the entry 
into the CSF via the tight BCSFB and passage through the 
CSF. This hypothesis was further supported by detecting 
eGFP-positive T cells localized along the proposed inva-
sion route from the ChP stroma, the medio-basal ventri-
cle wall, the apical corpus callosum (CC) and along the 
CC to the peri-ischemic infarct in lymphocyte-deficient 
Rag1−/− mice reconstituted with eGFP + T cells (Fig. 3e, 
f). Finally, to test the potential alternative migration route 
of T cells from the ChP to the cortex via the CSF, we 
blocked this migration pathway by matrigel injection into 
the ipsilateral ventricle (Fig. 3f). Matrigel—a non-toxic 
agent polymerizing at body temperature—was confined to 
the ipsilateral ventricle and did not diffuse to lower com-
partments (Fig. 3g). Moreover, this technique of block-
ing CSF flow and intraventricular leukocyte migration 
was previously shown to not induce neuroinflammation 
or affect ChP integrity [36]. Blocking of CSF flow by 
matrigel injection did not significantly alter T-cell counts 
at the peri-ischemic infiltration site compared to control-
operated mice (needle introduction and PBS injection), 
indicating that intraventricular lymphocytes as well as 
migration via the ventricular CSF space might not play 
a significant role for cerebral T-cell invasion after stroke 
(Fig. 3h).
Choroid plexus infarction reduces post‑stroke T‑cell 
invasion
Several previous reports demonstrated that experimen-
tal brain ischemia by transient, proximal occlusion of the 
Fig. 2  T cells migrate from the ChP to the peri-infarct cortex. a 
Schematic illustration of the experimental design to perform intraven-
tricular/ChP optical labeling of T cells for an “in vivo pulse-chase” 
experiment of intracerebral T-cell migration. b Representative pic-
ture of photoactivated PA-GFP+(green) and immunostained  CD3+ T 
(red) cells of ventricular origin in the peri-infarct cortex (marked by 
a cross). The nucleus is stained with DAPI (blue). Scale bar 10 µm. 
c Quantification of three independent animals per time point for 
PA-GFP-negative (red) and PA-GFP-positive (green) T cells, 4 days 
after pMCAo and indicated time points after illumination per one 
coronal section at the bregma level in the ipsilateral hemisphere. d 
Corresponding accumulative topographic maps of PA-GFP+CD3+ 
photoactivated T cells at the indicated time points after stroke from 
three individual animals. e Experimental design for estimating cer-
ebral T-cell counts entering via the ChP over a 24 h time period at the 
peak infiltration period after stroke (d4–d5). f Schematic illustration 
of the optogenetic setup for intraventricular photoactivation of PA-
GFP T cells. g Quantification of PA-GFP-negative (red) and PA-GFP-
positive (green) T cells, 4  days after pMCAo without illumination 
(n = 10) or with 24 h of constant illumination (n = 7) per one coronal 
section at the bregma level in the ipsilateral hemisphere and h cal-
culation of the percentage of ventricularly photoconverted PA-GFP+ 
and PA-GFP−CD3+ T cells in the ipsilateral hemisphere after sub-
traction of baseline T-cell counts before 24-h illumination at 4 days 
after pMCAo. All comparative analyses are illustrated as mean ± SD
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Fig. 3  Choroidal T cells directly invade the brain parenchyma. a, b 
Coronal image from a lectin-perfused, cleared brain. Arrows high-
light penetrating cerebral vessels to the ChP, indicating the ChP–
brain parenchyma junction. Scale bar 0.5  mm. c–d Lectin-perfused 
solvent-cleared brains have been imaged by light-sheet microscopy 
and segmented for brain parenchyma (blue), the ChP (green), ventri-
cle (yellow) and the corpus callosum (red) in order to illustrate the 
anatomical relation of these structures presumably involved in intra-
parenchymal T-cell migration. Arrows indicate the junction of the 
ChP stroma with the brain parenchyma at the mediobasal ventricle 
wall. Scale bar 0.5 mm. e Source image used for the 3D reconstruc-
tion shown in Fig.  1c. Arrows indicate eGFP  +  T cells which have 
been transferred to lymphocyte-deficient Rag1−/− mice for T-cell-
specific identification in solvent-cleared brains, scale bar 250  µm. 
f Experimental design to block intraventricular cell migration by 
injection of matrigel into the ipsilateral ventricle. g Representative 
image illustrating polymerized matrigel inside the left lateral ven-
tricle. Matrigel was supplemented with Evans blue for a better visu-
alization of the matrigel in this image. h Accumulative topographic 
maps and i quantification of  CD3+ T cells per one ipsilateral coro-
nal brain section at bregma location 5 days after pMCAo + Sham or 
pMCAo  +  matrigel treatment (n  =  6 per group, three independent 
experiments). Comparative analyses are represented as mean ± SD
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MCA (tMCAo model) resulted in substantially lower T-cell 
infiltration despite much larger infarcts than after perma-
nent, distal occlusion of the MCA (pMCAo model) [20, 47]. 
Following the previous results revealing the ChP as a key 
invasion route for cerebral T-cell invasion after stroke, we 
tested the hypothesis that proximal MCA occlusion might 
affect ChP function thereby resulting in reduced T-cell 
invasion. Hence, we analyzed T-cell infiltration 3 days after 
pMCAo or tMCAo (Fig. 4a). In accordance with our pre-
vious studies, large ischemic lesions in the tMCAo model 
resulted in significantly lower T-cell infiltration compared 
to cortical lesions in the pMCAo model (Fig. 4b). Impaired 
post-ischemic T-cell infiltration in the tMCAo model was 
associated with a more than twofold increase in TUNEL+ 
cells of the ipsilateral ChP stroma, while distal MCA occlu-
sion in the pMCAo model did not induce choroidal cell 
death compared to the contralateral control ChP (Fig. 4c, 
d). Ischemic lesion after proximal occlusion of the MCA is 
fully compatible with the transient occlusion of the anterior 
choroidal artery, which supplies predominantly the ChP and 
originates from the proximal MCA [3, 11]. To further cor-
roborate the critical role of the ChP in post-stroke T-cell 
invasion, we induced a localized photothrombotic (PT) 
lesion of the ipsilateral ChP directly after pMCAo by a laser 
probe introduced into the ipsilateral ventricle (Fig. 4e, f). 
5 days after surgery, cell death was observed specifically 
in the ChP after PT (Fig. 4f) and we detected a significant 
reduction in total cerebral T-cell counts in mice undergoing 
choroidal photothrombosis (pMCAo + PT) in comparison 
to sham-operated (pMCAo + Sham) mice (Fig. 4g, h). More 
specifically, choroidal infarction massively reduced corti-
cal T-cell invasion while some T cells were detected in the 
caudal ventricle region most likely as a reaction to the pho-
tothrombotic lesion itself (Fig. 4f, g). Notably, we did not 
detect a significantly difference in the infarct volume in mice 
with choroidal photothrombosis (pMCAo + PT) in compari-
son to sham-operated animals (pMCAo + Sham) (Fig. 4i) 
despite the substantial reduction in T-cell infiltration. These 
Fig. 4  Choroid plexus infarction reduces T-cell invasion after cor-
tical ischemia. a Cumulative topographic maps of one coronal sec-
tion from six mice (each dot represents one cell, infarct area shown 
in gray) and b quantitative analysis of T cells per one ipsilateral and 
contralateral hemisphere section at bregma level 3 days after pMCAo 
or tMCAo (n  =  6 per group). c Representative image of TUNEL+ 
(green) stained apoptotic cells within the ChP of the ipsilateral ven-
tricle 24  h after tMCAo; nuclear stain with DAPI (blue). Scale bar 
50 µm. d Quantitative analysis of TUNEL-positive cells per one ipsi-
lateral and contralateral ChP 24 h after pMCAo or tMCAo (n = 4–5). 
e Experimental design to test the role of the ChP in post-stroke T-cell 
infiltration by an isolated photothrombotic ChP lesion (PT-ChP). f 
Representative image of TUNEL+ (green) stained apoptotic cells 
within the ChP of the ipsilateral ventricle 5 days after pMCAo + PT-
ChP. Scale bar 500  µm. g Cumulative topographic maps of T cells 
from one section at bregma level from five mice per group, 5  days 
after pMCAo  +  Sham or pMCAo  +  PT-ChP surgery. h Quantifica-
tion of cortical T cells in both groups per one coronal section in the 
ipsilateral hemisphere and i infarct volume of both treatment groups 
(n = 5 per group)
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results clearly demonstrate the importance of the ChP for 
post-stroke T-cell infiltration, however, without affecting 
stroke severity in contrast to previous studies linking cer-
ebral T-cell infiltration to stroke outcome.
CCL2 chemokine gradient between the peri‑infarcted 
cortex and choroid plexus
We next aimed at investigating the molecular basis for the 
directed intracerebral migration of T cells from the ChP 
to the peri-infarct cortex and hypothesized an underly-
ing chemokine gradient between cortex and the ChP to be 
responsible for this fast intraparenchymal T-cell migration. 
Therefore, we performed a PCR array for 84 chemokines 
and chemokine receptors from microdissected samples of 
ChP and the peri-infarct cortex 24 h after pMCAO and con-
trol animals. We detected 23 up-regulated genes in the peri-
infarct compared to control cortex (Fig. 5a; Suppl. Table 4) 
and 18 up-regulated genes in the post-stroke ChP compared 
to control ChP (Fig. 5b; Suppl. Table 5), using twofold 
regulation and p < 0.1 as significant thresholds. Interest-
ingly, the two most abundantly upregulated chemokines 
in the cortex after stroke—CCL2 and CCL12—were also 
most highly upregulated in the post-ischemic ChP. How-
ever, overall chemokine upregulation was manifold higher in 
the peri-infarct cortex compared to the ipsilateral ChP with, 
e.g., more than 300-fold upregulation of CCL2 in the cortex 
compared to a tenfold upregulation in the ChP after stroke 
(Fig. 5a–c), suggesting a biologically relevant gradient for 
these chemokines between cortex and ChP. Notably, three 
out of the five most abundantly upregulated chemokines 
in the cortex as well as in the ChP are ligands of the CC 
chemokine receptor 2 (CCR2), namely CCL2, CCL12 and 
CCL7 [17, 19, 27]. This indicated a potentially relevant 
involvement of the CCR2 chemokine axis in post-ischemic 
T-cell attraction from the ChP to the peri-infarct cortex. To 
reveal the cellular source of cortical CCL2 expression after 
stroke, we performed a flow cytometric analysis of CCL2-
RFP reporter mice 24 h after stroke induction. Here, we 
detected  CD45low/intCD11b+ (presumably microglia) and 
 CD45highCD11b+ (presumably monocyte/macrophages) as 
the main RFP positive cells, however, with differences in 
CCL2-RFP expression levels between these two populations 
(Fig. 5d). While microglial cells displayed homogenous low-
intermediate CCL2-RFP expression levels, we detected two 
distinct subpopulations of  CD45highmonocytic cells with 
low/intermediate and high CCL2-RFP expression, respec-
tively (Fig. 5d, e). Next, we analyzed histologically coronal 
brain sections of CCL2-RFP reporter mice to test for the 
cellular source of the regional chemokine gradient suggested 
by the results of the PCR array. Indeed, after rasterizing 
the fluorescence intensity images and generating density 
maps, we detected a marked gradient of RFP expression 
with its center at the same anatomical area of predominant 
T-cell invasion in the peri-infarct cortex (Fig. 5f). Notably, 
this CCL2 gradient focusing in the peri-infarct cortex was 
observed already at early time points after stroke (24 h post-
lesion) preceding cerebral T-cell invasion and can, therefore, 
be assumed rather as a cause than a consequence of cortical 
T-cell clustering. Taken together, our chemokine screening 
analysis identified CCR2 ligands being substantially upregu-
lated after stroke and we were able to confirm a relevant 
CCL2 gradient also at the protein level, mainly secreted 
by innate immune cells in the peri-infarct cortex. Conse-
quently, we hypothesized that CCR2 might be involved in 
attraction of T cells from the ChP along the CCL2 gradi-
ent to the peri-infarct cortex. Analyzing the organ-specific 
frequency of  CCR2+ T cells in the peripheral immune com-
partment (spleen, blood) and the post-ischemic brain, we 
observed a substantial enrichment of  CCR2+ T cells in the 
ischemic hemisphere supporting a potential role of CCR2 
in cerebral T cells migration (Fig. 5g). We next aimed to 
block the CCR2 chemokine axis using CCR2−/− mice to 
probe its impact on post-stroke T-cell migration. CCR2-
deficiency indeed significantly reduced T-cell migration to 
the peri-infarct cortex. Interestingly, lack of CCR2 resulted 
in slightly increased T-cell counts in the corpus callosum 
(Fig. 5h). Notably, we did not detect a significant differ-
ence in infarct volume between groups, indicating a stroke 
severity-independent effect of CCR2 expression in T-cell 
migration (Fig. 5i). This finding suggests that chemotaxis 
driven by CCR2 ligands might be important for intracerebral 
Fig. 5  Intraparenchymal T-cell migration follows a CCR2-ligands 
gradient between peri-infarct cortex and choroid plexus. a, b Vol-
cano plot illustration of the regulation of gene expression of 84 
chemokines and chemokine receptors (upper panels) and bar graphs 
for top 5 regulated genes (lower panels) in a the cortex (CX) and 
b the ChP between 24 h after pMCAo or Sham surgery (n = 6 per 
group, 3 individual experiments per analysis). c Heat map of the 
top 10 upregulated genes in the cortex and ChP24h after pMCAo 
compared to Sham surgery, indicating substantial differences in 
the magnitude of regulation of the same genes in the CX and ChP 
after pMCAo. d Representative histogram of the expression inten-
sity of CCL2-RFP in the  CD45low/intCD11b+microglial population 
and  CD45highCD11b+ monocytes 24  h after pMCAo. e Quantifica-
tion of “high” and “low/intermediate” CCL2-RFP expression cells 
within the microglial and monocyte cell populations corresponding 
to the cell populations shown in panel D. f Illustration of rasterized, 
relative CCL2-RFP expression intensity normalized to the homotypic 
contralateral hemisphere (see “Materials and methods” section for 
details) 24  h after pMCAo in the ipsilateral hemisphere revealing a 
CCL2 focus in the peri-infarct cortex. Dashed line indicates the bor-
der to the infarct core. g Frequency of CCR2-positive cells among 
total T cells (CD3) was analyzed by flow cytometry 5  days after 
stroke in spleen, blood and the ipsilateral brain hemisphere. h Cumu-
lative topographic maps (left; 13 mice per group) and quantification 
(right) of T-cell counts 5 days after pMCAo in WT and  CCR2−/−mice 
per one coronal section in ipsilateral cortex and corpus callosum and i 
infarct volume of both groups (n = 13 per group, 2 individual experi-
ments)
◂
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migration along a chemokine gradient to the peri-infarct 
region but might not be involved for initial entry of T cells 
through the ChP.
The role of choroid plexus after stroke in humans
Next, we aimed to test the involvement of the ChP for post-
stroke cerebral T-cell invasion in human stroke patients. 
For this, we obtained autopsy samples of both lateral ven-
tricles from five stroke patients dying of other cause than 
stroke in the subacute phase after stroke onset and six con-
trol patients without cerebral infarction (Suppl. Table 2). 
By histological analysis for T cells (CD3) and monocytes/
macrophages (CD68) (Fig. 6a), we observed increased cho-
roidal T-cell counts in stroke patients compared to control 
patients (Fig. 6b). Moreover, in accordance with the results 
obtained in the mouse stroke models, T cells were the main 
cell population in the ChP of stroke patients (Fig. 6b). We 
then analyzed the chemokine expression in human samples 
of the peri-infarct cortex and the contralateral homotypic 
control cortex from autopsy samples of six patients, which 
had died in the acute phase after stroke (Suppl. Table 3). We 
performed a NanoString analysis for quantitative transcrip-
tional regulation of 561 inflammation-related human genes, 
revealing a distinct upregulation of 8 inflammatory genes 
in the peri-infarct cortex compared to the contralateral side 
Fig. 6  Choroid plexus cellularity and cortical chemokines in human 
stroke patients. a Representative images of a hematoxylin–eosin-
stained section of the human choroid plexus in the temporal horn 
of the lateral ventricle and surrounding brain tissue (left, scale bar 
1  mm), CD3+ T cell and CD68+ monocytes/macrophage stain-
ings (CD68) (right, scale bars 40 µm) used for subsequent analysis. 
b Quantitative analysis of the ratio between CD68 and CD3 posi-
tive cells in the ipsilateral ChP of control patients or stroke patients 
(n  =  5–6 per group, see Suppl. Table  2). c Volcano plot depicting 
the regulation of gene expression assessed by Nanostring analysis 
between the ipsilateral peri-infarct tissue and homotypic contralateral 
side in patients in the acute phase after ischemic stroke (see Suppl. 
Table 3). Red dots indicate the significantly upregulated genes in the 
peri-infarct tissue. d Bar graph showing fold regulation of the top 5 
significantly upregulated genes in the peri-infarct cortex compared to 
the contralateral hemisphere (n = 6 per group)
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(Fig. 6c). Also in these human samples, CCL2 was one of 
the overall most highly upregulated genes, and together with 
IL-8 (CXCL8) the only significantly upregulated chemokine 
(Fig.  6d; Suppl. Table  6). These results demonstrate a 
remarkable similarity for the cellular infiltration pattern as 
well as cortical chemokine expression after human stroke 
compared to the murine stroke model, suggesting that a com-
parable intraparenchymal T-cell migration from the ChP to 
the ischemic lesion might also occur after human stroke.
Discussion
We describe in this study the ChP as a previously unrec-
ognized critical invasion route for T cells into the ischemic 
brain after stroke. This finding of choroidal T-cell infiltra-
tion after stroke offers an explanation of previously elusive 
observations in the field of stroke immunology such as the 
specific clustering of T cells in the peri-infarct cortex, dif-
ferences in T-cell invasion between stroke models and finally 
the ineffectiveness of blocking post-stroke T-cell invasion by 
targeting endothelial adhesion molecules in several previous 
reports.
Lymphocyte infiltration after stroke has become a main 
research area in experimental stroke research due to the 
implication of post-stroke neuroinflammation in second-
ary brain damage [4, 44]. However, preclinical research on 
post-stroke neuroinflammation has repetitively experienced 
irreproducibility of findings between laboratories using dif-
ferent stroke models and reported substantial differences in 
the extent of neuroinflammation between commonly used 
mouse models of acute brain ischemia [8, 47]. While mod-
els of permanent ischemia in the cerebral cortex (pMCAo, 
photothrombosis, thrombin-injection model) have reproduc-
ibly resulted in a pronounced cellular neuroinflammation, 
more extensive lesions induced by transient occlusion of the 
proximal MCA resulted in less cerebral leukocyte infiltra-
tion [6, 20, 47]. In the present study, we observed that only 
transient, proximal MCA occlusion induced cell death in the 
ipsilateral ChP, most likely by occlusion of the supplying 
anterior choroidal artery. Taking into account that based on 
our results approximately 60% of cerebral T cells invade via 
the ipsilateral ChP, it seems plausible that differential ChP 
damage in some stroke models accounts for a large part of 
inter-laboratory and -model differences observed in previous 
studies on post-stroke neuroinflammation.
In contrast to the endothelium of the BBB, the ChP 
endothelium is fenestrated, facilitating cellular migration 
into the ChP stroma. On the other side, the tight junctions 
of the ChP epithelium contribute to the BCSFB by limiting 
paracellular transport of small molecules and immune cell 
entry into the CSF [29, 35, 38]. These anatomical proper-
ties of the ChP implicate that circulating leukocytes can 
easily enter the ChP stroma but crossing the epithelial layer 
into the CSF would be far more energy demanding. Previ-
ous studies have proposed that ChP-resident T cells can be 
readily mobilized for cerebral invasion under inflammatory 
conditions. T cells in the ChP have in principle two routes 
to invade the brain parenchyma: crossing the epithelial layer 
into the CSF and invading the brain from the CSF at dif-
ferent sites or migrate from the ChP stroma directly into 
the brain parenchyma at the base of the ChP. The involve-
ment of both invasion pathways for T cells from the ChP 
stroma have been barely investigated under physiological 
conditions or inflammatory brain disorders; nevertheless, 
the migration pathway via the CSF has been assumed in the 
majority of studies analyzing the ChP in autoimmune brain 
diseases [13, 33]. Yet, the migration of lymphocytes across 
the BCSFB remained questionable as the key adhesion mol-
ecules involved in this process—ICAM-1 and VCAM-1—
are exclusively expressed on the apical side of ChP epithelial 
cells, thus, not accessible for stromal lymphocytes to enter 
the CSF [37, 46]. This means that key adhesion molecules 
which are expressed and critical for cell trafficking at the 
BBB are also expressed in the ChP but are not functional for 
T-cell invasion to the ChP because these molecules are not 
accessible for circulating leukocytes. This is of high clinical 
relevance, as the specific inhibition of endothelial or leuko-
cyte adhesion molecules involved at the BBB failed so far 
to improve clinical outcome in stroke patients [12, 16] in 
contrast to numerous preclinical studies showing improved 
stroke outcome by depleting or reducing circulating lym-
phocytes. These discrepant findings might be attributable to 
the wrong assumption that cerebral T-cell invasion occurs 
along the vascular invasion routes, thereby targeting vascular 
adhesion molecules that play only a minor role at the ChP.
The results from our study unexpectedly suggest a rapid 
and directed T-cell migration from the ChP to the brain 
parenchyma. We have demonstrated the previously insuf-
ficiently investigated attachment of the ChP in the mouse 
lateral ventricle at the basomedial ventricle wall as a pos-
sible entry site for T cells into the CNS. Border structures 
such as tanycytes surrounding circumventricular organs or 
other cell types with tight intercellular junctions have to our 
knowledge not been described at the ChP base. The junc-
tion of the ChP to the brain parenchyma remains, therefore, 
a matter of debate and further neuroanatomical studies are 
urgently needed to clarify the anatomical basis for direct 
cell entry from the ChP stroma to the brain parenchyma. 
Here, we identified T cells after photoactivation in the ChP 
along the ChP–parenchyma junction, the corpus callosum 
and the peri-infarct cortex. Moreover, inhibition of CSF 
circulation did not affect cerebral T-cell invasion, strongly 
supporting a not yet considered migration from the ChP 
stroma into the brain parenchyma. Additional indirect indi-
cation for this novel migration pathway was the surprisingly 
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fast kinetics of T-cell translocation from the ventricle/ChP 
after photoactivation to the peri-infarct cortex within only 
few hours, which seems neither compatible with the pas-
sive transport of ventricular T cells along CSF flow nor the 
highly energy-demanding and tightly regulated migration 
across the BCSFB into the lateral ventricle and then across 
the ventricular ependymal cell layer directly into the fore-
brain parenchyma.
Results from our experiments in CCR2−/− mice support 
the concept of CCR2-dependent intraparenchymal migra-
tion of T cells after the parenchymal invasion from the ChP 
stroma. While potential mechanisms in ChP activation and 
recruitment of inflammatory cells into the ChP have previ-
ously been studied—and Type I Interferons been defined 
as key mediators—molecular cues for intraparenchymal 
T-cell migration have to our knowledge previously not 
been characterized. We have observed a distinct gradient 
for CCR2 ligands (i.e., CCL2, CCL7, CCL12) between the 
peri-infarct cortex and the ipsilateral ChP and have addition-
ally defined innate immune cells in the peri-infarct cortex 
as their main source. However, we cannot exclude that the 
observed effects in the CCR2−/− model might be at least par-
tially due to a generally ameliorated inflammatory milieu in 
the ischemic brain as we used in these experiments a global 
CCR2-knockout model. Particularly, studies in models of 
primary autoimmune neuroinflammation have shown a key 
role of CCR2 in recruiting monocytes and dendritic cells 
to the inflamed brain [7]. On the other side, a study by Chu 
et al. using a permanent MCA occlusion model as in our 
study revealed CCR2-independent recruitment of inflam-
matory monocytes to the ischemic brain [5] and resident 
microglial cells are sufficient to produce large amounts of 
T-cell-attractive CCL2 in response to brain injury [15, 40].
Based on the results from our study showing a predom-
inant T-cell infiltration via the ChP route, it is conceiv-
able that previous preclinical studies as well as current 
clinical trials testing specific blockage of T-cell migration 
across the BBB after acute brain ischemia might have 
been hampered by the alternative choroidal invasion 
route. Finally, further alternative invasion routes such 
as the meningeal entry site need to be further investi-
gated [2]. Additional studies characterizing the distinct 
adhesion molecules involved at migration across the dif-
ferent brain barriers of the BBB, the BCSFB or alterna-
tive invasion sites such as the meninges are inevitable 
for the rationale design of clinical stroke trials targeting 
at cerebral T-cell invasion. Notably, results from previ-
ous studies analyzing both invasion routes into the brain 
under conditions of primary autoimmune neuroinflam-
mation might be of only limited value due to the specific 
properties of stroke-induced inflammation such as the 
acute onset, pronounced glial activation and additional 
peripheral immunomodulation. Besides the complexity of 
various potential invasion routes of inflammatory leuko-
cytes after acute brain, evasion pathways for lymphocytes 
from the post-ischemic brain to exit the brain and poten-
tially re-enter the blood stream are unknown. Various 
routes have previously been described for lymphocytes 
to exit the brain parenchyma under inflammatory condi-
tions including a recently described cerebral lymphatic 
system [22]. However, the contribution of potential eva-
sion mechanisms for cerebral lymphocyte turnover rates 
after stroke is unknown. Therefore, the model in this 
study revealing rapid translocation from the ChP to the 
peri-infarct cortex in UBC-PA-GFP mice is limited by the 
assumption of a static system with no substantial T-cell 
turnover within 24 h after cell invasion.
Taken together, we observed an unexpected role of the 
ipsilateral ChP in the lateral ventricle as the major inva-
sion route for T cells into the ischemic brain after stroke. 
We have defined the intracerebral migration route from 
the ChP into the peri-infarct cortex via a ChP–parenchyma 
junction, detected a potential chemokine gradient involved 
in the intraparenchymal migration and confirmed similar 
mechanisms in the human brain after acute stroke. These 
results question previously accepted concepts and thera-
peutic strategies in post-stroke neuroinflammation and are 
of direct clinical relevance for current and planned clinical 
trials testing therapies for inhibiting post-stroke cerebral 
leukocyte invasion.
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Supplementary figure 2. Monocyte and T cell quantification in the brain parenchyma and choroid plexus (ChP) 5
days after pMCAo from one section at bregma level. Comparative analysis are represented as mean±SD (n=5).
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Experiment Total animals Included animals
Excluded 
animals
Reason for 
exclusion
lysM-eGFP
immunostaining 19 19 0 -
CD3 
immunostaining 24 24 0 -
CD45
immunostaining 36 36 0 -
Brain FACS 10 10 0 -
ChP FACS 18 18 0 -
Phototrombosis 10 9 1 Death duringsurgery
Aged animals 5 5 0
TBI 5 5 0 -
PA-GFP 5min 
illumination 15 15 0 -
PA-GFP 24h 
illumination 22 21 1
Death during
cannula
implantation
Matrigel
experiment 12 6 6
Death during
matrigel
injection
tMCAo 4 4 0 -
pMCAo+PTCP 5 5 0 -
Chemokines
and 
chemokines
receptor 
experiment
6 6 0 -
CCL2-RFP 13 13 0 -
CCR2–/– 13 13 0 -
Supplementary table 1. Number of excluded animals of the different experiments
Patient Age (years) Sex Known comorbidities Autolysis time (h) Infarct location
Stroke 1 72 Male COPD* 11.8 Right parietal lobe
Stroke 2 86 Male Myocardial infarction 14.5 Right basal ganglia
Stroke 3 84 Male - 14.0 Right frontal lobe
Stroke 4 77 Male Congestive heart failure 12.3 Right thalamus
Stroke 5 70 Male Pancreatic cancer# 18.2 Right parietal lobe
Stroke 6 79 Female - 15.7 Right frontal lobe
Control 1 90 Male COPD* 17.8 -
Control 2 84 Female Alzheimer's disease 14.0 -
Control 3 84 Female Alzheimer's disease, pneumonia 12.5 -
Control 4 88 Female Atherosclerosis 14.0 -
Control 5 72 Female Ovarian cancer# 14.0 -
*Chronic Obstructive Pulmonary Disease; #No cerebral metastasis; none of the patients received thrombolysis
Supplementary table 2. Characteristics of human patients for choroid plexus immunohistological analysis
Patien
t
Age (years) Sex Time from onset to 
death
Post-mortem
interval
tPA
treatment
Infarct location
N2 91 Femal
e
70h 6h No Left hemisphere
N3 59 Male 75h 4h No Right 
hemisphere
N22 67 Male 62h 7h Yes Left hemisphere
N24 83 Femal
e
100h 14.5h Yes Left hemisphere
N33 80 Male 101h 4.5h No Right 
hemisphere
N35 84 Male 40h 8h No Left hemisphere
Supplementary table 3. Characteristics of human patients for Nanostring analysis
Supplementary table 4. Fold upregulated genes in the cortex after pMCAo in mice 
Gene Fold up-regulation p value
Ccl2 336.081 0.047
Ccl12 232.218 0.115
Ccl4 214.426 0.005
Cxcl10 160.267 0.013
Ccl7 95.847 0.031
Tnf 84.215 0.049
Ccl11 77.673 0.083
Cxcl1 41.672 0.041
Ccl3 41.480 0.035
Cxcl2 25.771 0.281
C5ar1 18.713 0.082
Cxcl3 16.905 0.316
Il6 15.591 0.154
Ccr1 13.542 0.090
Ccl20 8.590 0.054
Ccl8 8.336 0.014
Cxcl16 7.941 0.032
Cxcr2 7.010 0.279
Tlr2 5.615 0.004
Ccl9 5.500 0.038
Cxcr4 4.804 0.076
Ccl5 3.898 0.096
Cxcr5 3.826 0.167
Ccr2 3.591 0.266
Ccr7 3.501 0.009
Ccl6 3.370 0.068
Il1b 3.229 0.299
Ccr4 2.957 0.269
Ccr5 2.947 0.004
Itgb2 2.867 0.093
Cxcl5 2.737 0.094
Fpr1 2.690 0.046
Ccl28 2.510 0.159
Ppbp 2.481 0.164
Ccr3 2.055 0.236
Cmklr1 2.048 0.190
Tlr4 1.867 0.413
Cmtm3 1.736 0.001
Cxcl9 1.720 0.196
Tgfb1 1.662 0.671
Ccl1 1.499 0.818
Pf4 1.453 0.567
Gene Fold up-regulation p value
Il4 1.409 0.462
Ackr2 1.389 0.306
Il16 1.289 0.611
Ccl19 1.284 0.388
Xcl1 1.275 0.621
Ccl25 1.231 0.231
Ccr10 1.147 0.946
Xcr1 1.142 0.843
Ccl17 1.123 0.726
Itgam 1.110 0.939
Cxcr1 1.093 0.550
Ccr6 1.078 0.443
Ccrl2 1.069 0.859
Darc 0.993 0.821
Cmtm2
a 0.975 0.408
Cx3cr1 0.966 0.924
Cxcr6 0.952 0.921
Ccl22 0.940 0.572
Ccr8 0.930 0.707
Tymp 0.917 0.714
Cmtm6 0.906 0.540
Hif1a 0.878 0.417
Ccl24 0.876 0.337
Slit2 0.851 0.593
Ifng 0.840 0.371
Cxcl13 0.826 0.519
Ackr3 0.792 0.407
Cxcl11 0.776 0.513
Cxcr3 0.760 0.902
Ackr4 0.751 0.404
Cxcl15 0.698 0.356
Mapk1 0.694 0.346
Ccr9 0.681 0.525
Cxcl14 0.644 0.054
Cmtm4 0.644 0.070
Mapk14 0.613 0.203
Ccr1l1 0.551 0.265
Cmtm5 0.522 0.321
Cx3cl1 0.475 0.049
Ccl26 0.327 0.295
Gpr17 0.289 0.130
Cxcl12 0.228 0.151
Gene Fold up-regulation p value
Ccl9 1.326 0.297
Mapk1 1.325 0.185
Ccl6 1.289 0.294
Tgfb1 1.289 0.281
Ccr1 1.277 0.341
Ccl19 1.265 0.219
Ccl25 1.259 0.402
Tlr2 1.245 0.327
Ccr10 1.222 0.491
Il1b 1.193 0.203
Il16 1.164 0.451
Ccr9 1.161 0.609
Gpr17 1.118 0.912
Cxcr6 1.100 0.595
Mapk14 1.097 0.566
Tlr4 1.092 0.721
Cmtm6 1.082 0.783
Cmtm2
a 1.047 0.919
Hif1a 1.025 0.685
Cmtm4 1.010 0.903
Cxcl3 1.010 0.676
Cxcl16 -1.025 0.731
Ccr1l1 -1.035 0.871
Ccl5 -1.053 0.760
Slit2 -1.134 0.929
Cxcr2 -1.333 0.305
Ifng -1.353 0.582
Cxcl12 -1.372 0.897
Cxcl2 -1.393 0.897
Ackr2 -1.404 0.994
Cxcr3 -1.414 0.822
Ccrl2 -1.475 0.518
Ackr4 -1.601 0.855
Ccr2 -1.603 0.432
Pf4 -1.673 0.792
Cxcl15 -1.691 0.780
Ccr8 -1.829 0.427
Xcl1 -1.951 0.112
Cxcl11 -2.079 0.262
Ppbp -2.099 0.632
Cxcl13 -2.228 0.625
Xcr1 -3.649 0.148
Gene Fold up-regulation p value
Ccl12 11.424 0.022
Ccl2 9.409 0.019
Cxcl5 8.489 0.063
Cxcl1 8.392 0.063
Ccl11 6.684 0.016
Cxcl9 5.614 0.108
Darc 4.944 0.029
Ccl7 4.072 0.013
Ccl20 3.848 0.052
Cxcr5 3.738 0.101
Il6 3.400 0.089
Ccl8 3.389 0.202
Tnf 3.377 0.056
Ccl1 3.089 0.089
Cxcl14 2.998 0.078
Il4 2.947 0.092
Cxcl10 2.775 0.132
Ccl28 2.746 0.088
Ccl4 2.718 0.201
Itgam 2.565 0.018
Ccl3 2.416 0.121
Ccr4 2.393 0.180
Tymp 2.285 0.094
Fpr1 2.197 0.012
Ccr6 2.091 0.082
Ccl22 2.062 0.171
Ccl26 2.020 0.107
C5ar1 2.017 0.216
Ccl17 1.987 0.022
Cxcr4 1.987 0.289
Itgb2 1.937 0.064
Cx3cr1 1.915 0.010
Cxcr1 1.781 0.233
Cx3cl1 1.605 0.061
Ccl24 1.575 0.355
Cmklr1 1.453 0.281
Ccr3 1.448 0.311
Ccr7 1.441 0.708
Cmtm5 1.392 0.240
Ccr5 1.371 0.109
Ackr3 1.371 0.274
Cmtm3 1.328 0.163
Supplementary table 5. Fold upregulated genes in the ChP after pMCAo in mice 
Supplementary table 6. Significantly upregulated genes in the 
peri-infarct cortex after stroke in humans (Nanostring)
Gene Fold up-regulation
p value 
(<0.05)
IL8 5.0 0.040
CCL2 4.9 0.011
TNFAIP
3 4.2 0.023
LIF 4.1 0.047
IL6R 3.7 0.016
CXCL1 3.6 0.036
ICAM1 3.6 0.051
IL6 3.4 0.068
NFKB2 3.3 0.018
TNFRS
F1B 3.0 0.042
CXCL2 2.9 0.070
TGFBI 2.9 0.170
CD163 2.8 0.170
ITGAX 2.8 0.051
PLAUR 2.8 0.098
PTGS2 2.8 0.180
FCGR2
A 2.6 0.130
MARC
O 2.6 0.078
NFIL3 2.6 0.081
CLEC5
A 2.5 0.120
CXCR4 2.5 0.096
IL18R1 2.5 0.095
SPP1 2.5 0.220
CFB 2.3 0.170
CTSC 2.2 0.100
IFI16 2.2 0.083
CXCL1
2 2.1 0.120
FCER1
G 2.1 0.130
LCP2 2.1 0.130
SOCS3 2.1 0.310
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Results of a preclinical randomized controlled
multicenter trial (pRCT): Anti-CD49d treatment for
acute brain ischemia
Gemma Llovera,1,2 Kerstin Hofmann,1,2 Stefan Roth,1,2 Angelica Salas-Pérdomo,3,4
Maura Ferrer-Ferrer,3,4 Carlo Perego,5 Elisa R. Zanier,5 Uta Mamrak,1,2 Andre Rex,6 Hélène Party,7
Véronique Agin,7 Claudine Fauchon,8 Cyrille Orset,7,8 Benoît Haelewyn,7,8
Maria-Grazia De Simoni,5 Ulrich Dirnagl,6 Ulrike Grittner,9 Anna M. Planas,3,4 Nikolaus Plesnila,1,2
Denis Vivien,7,8 Arthur Liesz1,2*
Numerous treatments have been reported to provide a beneficial outcome in experimental animal stroke models;
however, these treatments (with the exceptionof tissueplasminogenactivator) have failed in clinical trials. To improve
the translation of treatment efficacy from bench to bedside, we have performed a preclinical randomized controlled
multicenter trial (pRCT) to test a potential stroke therapy under circumstances closer to the design and rigor of a
clinical randomized control trial. Anti-CD49d antibodies, which inhibit themigration of leukocytes into the brain, were
previously investigated in experimental stroke models by individual laboratories. Despite the conflicting results from
four positive and one inconclusive preclinical studies, a clinical trial was initiated. To confirm the preclinical results and
to test the feasibility of conducting a pRCT, six independent European research centers investigated the efficacy of
anti-CD49d antibodies in two distinct mouse models of stroke in a centrally coordinated, randomized, and blinded
approach. The results pooled from all research centers revealed that treatment with CD49d-specific antibodies signif-
icantly reducedboth leukocyte invasionand infarct volumeafter thepermanentdistal occlusionof themiddle cerebral
artery, which causes a small cortical infarction. In contrast, anti-CD49d treatment did not reduce lesion size or affect
leukocyte invasion after transient proximal occlusion of themiddle cerebral artery, which induces large lesions. These
results suggest that thebenefits of immune-targeted approachesmaydependon infarct severity and localization. This
study supports the feasibility of performing pRCTs.m
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oINTRODUCTION
Ischemic stroke, a leading cause of death and disability worldwide (1),
induces the rapid loss of specific brain functions, a result of insufficient
blood flow to specific brain regions. Together with other downstream
effects, stroke triggers an acute inflammatory response in the brain,
which activates harmful signaling cascades that contribute to secondary
brain damage (2). Although stroke places enormous medical and eco-
nomic burdens on society, thrombolysis with tissue plasminogen acti-
vator (tPA) is currently the only clinically approved therapy for
ischemic stroke. Safety considerations require, however, that tPA must
be administered within a very narrow time window after the onset of
symptoms, and tPA treatment has important contraindications such as
hemorrhage or oral anticoagulation (3, 4). Because of these constraints,1Institute for Stroke and Dementia Research, Klinikum der Universität München, Feodor-
Lynen-Straße 17, 81377Munich, Germany. 2MunichCluster for SystemsNeurology (SyNergy),
81377Munich, Germany. 3Department of Brain Ischemia and Neurodegeneration, Institut
d’Investigacions Biomèdiques de Barcelona (IIBB), Consejo Superior de Investigaciones
Científicas (CSIC), 08036 Barcelona, Spain. 4Àrea deNeurociències, Institut d’Investigacions
Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain. 5Neuroscience Department,
IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, 20156 Milan, Italy. 6Department of
Experimental Neurology and Center for Stroke Research Berlin (CSB), Charité–Universitätsme-
dizin Berlin; German Center for Neurodegenerative Diseases (DZNE) and German Center for
Cardiovascular Diseases (DZHK), Berlin sites; Excellence Cluster NeuroCure, 10117 Berlin,
Germany. 7INSERM,UMR-SU919, Université deCaenBasse-Normandie, teamSerine Proteases
and Pathophysiology of the neurovascular Unit, GIP Cyceron, F-14074 Caen Cedex, France.
8Experimental Stroke Research Platform (ESRP), IBiSA platform, Centre Universitaire de
Ressources Biologiques (CURB), Université de Caen Basse-Normandie, F-14074 Caen Cedex,
France. 9Department of Biostatistics and Clinical Epidemiology, Charité–Universitätsmedizin
Berlin, 12203 Berlin, Germany.
*Corresponding author. E-mail: arthur.liesz@med.uni-muenchen.de
www.ScientPA is only provided to a small percentage of all stroke patients in in-
dustrialized countries; the overall therapeutic impact of tPA is negligible
when developing countries are also considered.
In recent decades, several experimental therapies have been developed
and tested for their ability to mitigate stroke-related brain injury, which
can include postischemic, excitotoxic neuronal damage, spreading de-
polarization, apoptosis, and/or inflammation (5, 6). Unfortunately, none
of the tested drugs that show promise in animal models of stroke have so
far been translated into clinical use for stroke patients (7, 8), and most
major pharmaceutical companies have stopped research and develop-
ment in this area. The cause of this failure in clinical trials ismultifactorial
and may include poorly designed preclinical and clinical studies, biased
selection of substances for clinical testing, and underpowered clinical
trials with overambitious and pathophysiologically irrelevant therapeutic
windows (5, 9). Indeed, academic and industrial researchers, as well as
funding agencies and journals, now recognize the existence of a “repro-
ducibility crisis”: the results of preclinical studies in many research fields,
including stroke, lack robustness, and only a small fraction of these stu-
dies can be replicated (10).
To overcome the current limitations of preclinical in vivo studies,
strict operational and statistical guidelines have been developed for
the data reporting, and suggestions have been implied for design and
performance of preclinical studies (11). In addition, pRCTs have been
proposed as a way to help bridge the gap between experimental labora-
tory research and clinical trials (12–14). Such studieswould be primarily
confirmatory, designed to test efficacy of previously defined therapeu-
tic concepts in a study design with the highest standards for statistics,
analysis, and reporting (15). Finally, such a studywill havemany of theceTranslationalMedicine.org 5 August 2015 Vol 7 Issue 299 299ra121 1
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 characteristics of adequately powered clinical trials. Several internation-
al consortia have been established to perform such studies, and multi-
center investigations have been reported, but no pRCT has been
published to date. Therefore, our objective was to implement a pre-
clinical multicenter trial by applying rigorous design, experimental,
and analysis standards to test the efficacy of an anti-inflammatory ther-
apeutic intervention (that is, blocking leukocyte migration with anti-
CD49d antibodies) in two experimental models of stroke.
Brain leukocyte invasion is a keymechanism thatmediates secondary
neuronal injury after an acute brain lesion (2, 16). Transendothelial
migration is tightly regulated by adhesion molecules, specifically the in-
teraction between the molecules VLA-4 (leukocyte very late antigen-4)
and VCAM-1 (vascular cell adhesion molecule-1) (17, 18). Antibodies
against the a chain of VLA-4 (anti-CD49d antibodies) have shown ef-
ficacy in several models of autoimmune diseases, and the humanized
antibody natalizumab is currently one of the most effective therapies
for patients with multiple sclerosis (19). Four single-center studies re-
ported that anti-CD49d antibodies confer cerebroprotective proper-
ties in mouse models of brain ischemia by blocking the postischemic
invasion of leukocytes into the brain (20–23). However, one of these
studies reported different efficacies between different stroke models
(20). The neuroprotective potential of anti-CD49d treatment was chal-
lenged further by a subsequent study that reported no treatment effect
(24). A phase 2 clinical trial is currently testing the effect of natalizumab
in patients after acute ischemic stroke (ClinicalTrials.gov identifier:
NCT01955707).
The availability of reliable preclinical data is essential for selecting
the drug candidates with the highest clinical potential and for designing
the most effective clinical study, thereby minimizing unnecessary, cost-
ly, and even harmful clinical trials. We therefore tested anti-CD49dwww.ScienceTranslationalMedicine.org 5treatment in a multicenter, randomized
preclinical trial. The predetermined pri-
mary end point for the trial was infarct
volume measured in two ischemic stroke
models. The secondary end points were
functional outcome and the invasion of
leukocytes into the brain.RESULTS
For this experimental trial, we used two
different models of focal brain ischemia
(Fig. 1, A to C) to address potential patho-
physiological differences among com-
monly used stroke models (25, 26). Small
lesions confined to the cortex were induced
by coagulation of the distalmiddle cerebral
artery (cMCAO), whereas lesions in the
cortex and subcortical structures were in-
duced by transiently occluding the MCA
at its origin for 60minwith an endovascular
filament (fMCAO). A total of 315 male
C57BL/6J mice from the following five
independent European research centers
were randomized in this trial by the author
indicated by their initials [center 1: Caen
(D.V.), center 2: Milan (M.-G.D.S.), center3: Barcelona (A.M.P.), center 4: Munich (N.P.), and center 5: Berlin
(U.D.)], whereas the sixth center centrally coordinated the study and
analyzed the data (Munich, A.L.). A total of 81 and 174 mice were in-
cluded in the final analyses of the cMCAO and fMCAO groups, respec-
tively (Fig. 1D). The animals’ physical features, mortality incidences,
and reasons for exclusion are summarized in Table 1. The body temper-
ature of themice at center 3 differed significantly from the other centers,
and the body weight of the mice at center 4 differed significantly from
the other centers; however, all values were within their respective nor-
mal physiological range for mice.
Anti-CD49d treatment reduces infarct volume after
cortical stroke
Previous studies performed in individual laboratories with relatively
small sample sizes suggested that anti-CD49d antibodiesmight improve
outcome after stroke (20–23); in contrast, another study reported no
significant benefit of this treatment (24). We therefore examined the
efficacy of anti-CD49d treatment in experimental ischemic stroke by
performing a pRCT, using pooled infarct volume of all centers per each
stroke model as the primary end points. The anti-CD49d antibody or a
control immunoglobulin G (IgG) antibody (300 mg each) was ad-
ministered intraperitoneally in a randomized and blinded fashion
3 hours after stroke induction.Analysis of thepooleddata fromall centers
revealed that treatment with anti-CD49d antibodies resulted in 19%
smaller infarct volume 7 days after cMCAO compared to administration
of control IgG (P < 0.05) (Fig. 2A). In contrast, 4 days after inducing
fMCAO, infarct volume did not differ between control IgG–treated
andanti-CD49d–treatedmice, regardlessofwhether thedatawereanalyzed
for each individual center or as a pooled data set (Fig. 2B). To addi-
tionally show the effect sizes (ESs, standardized mean difference) ofFig. 1. Animalmodels andanal-
ysis diagram. (A) Illustration of
the circle ofWillis looking caudal-
ly from the rostral side, indicat-
ing the MCAs with the distal or
proximal occlusion sites used in
the cMCAOor fMCAOmodels, re-
spectively. ACA, anterior cerebral
artery; BA, basilar artery; PCA,
posterior cerebral artery; ICA, in-
ternal carotid artery. (B and C)
Representative cresyl violet (CV)–
stained sections 7 days after cMCAO
(B)or4daysafter fMCAO(C).Dashed
lines demarcate the lesion area.
(D) Protocol diagram summariz-
ing the number of animals included (incl) (315 mice), with exclusion (excl) per group and included animal
numbers for final analysis. Exclusion criteria were defined as described in Materials and Methods. “†” in-
dicates dead animals.August 2015 Vol 7 Issue 299 299ra121 2
R E S EARCH ART I C L E
on
 A
ug
us
t 5
, 2
01
5
D
ow
nl
oa
de
d 
fr
om
 
9
N
v
fM
1
1
C
fo
(C
te
p
antibody treatment in the two stroke models, we performed a meta-
analysis using inverse-variance weighting (random-effects model)
from all centers; these results are illustrated as a forest plot (Fig. 2C).www.ScienceTranslationalMedicine.org 5Consistent with the results from the mixed
model analysis used to test the primary end
point (Fig. 2, A and B), the result from the
cMCAO model showed no significant ef-
fect of treatment if analyzed separately
for each center, whereas a subtotal analysis
(pooled for cMCAO) revealed a signifi-
cant treatment effect [ES, 0.57; 95% con-
fidence interval (CI), 0.01 to 1.13]. As in
the mixed model primary analysis, no
significant effect was found in the anal-
ysis forpooled infarct volumeafter fMCAO.
When the data were pooled from all treat-
ment centers and both models, the ES no
longer favored treatment (ES, 0.23; 95%
CI, −0.1 to 0.55).
Next, we investigated the accuracy of
our assessment of the primary end point.
Infarct volume was independently mea-
sured by two researchers (G.L. and A.L.)
at the central study center. These researchers
were blinded with respect to the groups,
and concordance of their results was con-
firmed using Bland-Altman analysis and
calculation of intraclass correlation co-
efficient (ICC), which revealed excellent
interrater reliability (ICC, 0.99; 95% CI,
0.990 to 0.994; Fig. 2D and fig. S1A).
Moreover, each study center reevaluated
the infarct volumes of the samples, con-
firming reliability between the central anal-
ysis and the analyses from each center (ICC
range, 0.88 to 0.99; fig. S1B). Together, these
results support the hypothesis that anti-
CD49d treatment reduces infarct volume
in cortical lesions after permanentMCA oc-
clusion; moreover, our results suggest thattreatment efficacy might depend on infarct type and severity, because
anti-CD49d treatment was not effective after transient occlusion of the
proximal MCA.Table 1. Animal characteristics.Center
Stroke
modelTime after lesion
(days)Total
n
Mortality
Exclusion: No
infarct
Exclusion: Other
criteria*
Final
n
A
Mean body
temperature†ugust 2015 Vol 7 Issue 2Mean body
weight1 Filament 4 45 1 9 1 34 37.43 25.022 Filament 4 45 9 6 — 30 37.88 23.133 Filament 4 45 6 3 — 36 38.77‡ 23.354 Filament 4 45 — — — 45§ — 20.60‡5 Filament 4 45 7 2 7 29 37.95 24.811 Coagulation 7 30 — — — 30 37.51 24.622 Coagulation 7 30 — 2 2 26 37.74 23.393 Coagulation 7 30 — 5 — 25 38.35‡ 23.88*Other exclusion criteria: Neuroscore <8 at 24 hours after fMCAO, overt mechanical damage, or disruption of the brain sample or sham animals with lesion. †Baseline values before
anesthesia induction. ‡P < 0.05 [analysis of variance (ANOVA)]. §P < 0.05 (c2).Fig. 2. Primary endpoint analysis. (A) In-
farct volumes 7 days after cMCAO with
isotype IgGcontrol or anti-CD49d treatment
3 hours after MCAO induction. Results are
presented per individual contributing cen-
ter [center 1: n(IgG control): 10, n(anti-CD49d):
10; center 2: n(IgG control): 8, n(anti-CD49d):; and center 3: n(IgG control): 7, n(anti-CD49d): 8] and as pooled samples from all centers [N(IgG control): 25,
(anti-CD49d): 27]. Mixed model analysis revealed significantly (b = 1.8, SE = 0.8, P = 0.027) lower infarct
olumes in the anti-CD49d treatment group. (B) Corresponding results for infarct volumes 4 days after
CAO (b = −0.3, SE = 3.3, P = 0.947). Results are presented per individual contributing center [center
: n(IgG control): 11, n(anti-CD49d): 9; center 2: n(IgG control): 6, n(anti-CD49d): 9; center 3: n(IgG control):
2, n(anti-CD49d): 9; center 4: n(IgG control): 15, n(anti-CD49d): 15; and center 5: n(IgG control): 5, n(anti-
D49d): 9] and as pooled samples from all centers [N(IgG control): 49, N(anti-CD49d): 51]. Center labels
r contributing centers are consistent between the two stroke models. Data are presented as means ± SD.
) Forest plot of ES estimation by the inverse-variancemethod in a random-effects model in individual cen-
rs and in all-center pooled data, corresponding to centers depicted in (A) and (B). (D) Bland-Altman
lot for interrater concordance of infarct volumemeasurement for the two independent and blinded raters
at the central study center. LA, limit of agreement.99 299ra121 3
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Anti-CD49d treatment reduces the invasion of leukocytes
into the brain after cortical stroke
Previous studies (20, 24) suggested that anti-CD49d treatment exerts its
primary therapeutic effect on brain ischemia by inhibiting leukocyte
invasion of the brain. To investigate this process, we prepared brain
sections from mice after MCAO or sham surgery; we then immuno-
stained the sections with antibodies against CD45, a marker for leuko-
cytes (Fig. 3A). The stained sections were analyzed by researchers who
were blinded with respect to the surgical and treatment groups.
Cumulative topographic maps of leukocyte invasion after cMCAO re-
vealed that leukocytes infiltrated the region surrounding the infarct
core, with predominant localization in the peri-infarct cortical area
(Fig. 3B). Anti-CD49d treatment significantly (P < 0.001) reduced the
number of leukocytes in the infarct area after cMCAO (Fig. 3, B and C),
consistent with our finding of reduced lesion volume in anti-CD49d–
treated mice after cMCAO. Mice that underwent fMCAO had signifi-
cantly fewer cerebral leukocytes than those thatunderwentMCAOcMCAO
[mean (SD), 5.4 (3.6) versus 11.4 (4.4) cells per section, respectively; P <
0.001], and anti-CD49d treatment did not affect the invasion of leukocytes
after fMCAO (Fig. 3D). Because of the high variability in lesion size and
location in the fMCAOmodel, we were unable to generate topographic
maps; however, we measured a weak yet significant inverse correla-www.ScienceTranslationalMedicine.org 5tion between infarct volume and cerebral
leukocyte count in the fMCAO-induced
group (Fig. 3E), suggesting a relationship
between lesion size and cellular poststroke
neuroinflammation.
Other secondary outcome
parameters were not affected by
anti-CD49d treatment
In addition to the infiltration of leukocytes
into the brain, we also measured the
following outcomes as predefined second-
ary end points: mortality, physiological
parameters, and behavioral deficits. Our
analysis revealed that none of these out-
comes was significantly affected by anti-
CD49d treatment. For the cMCAOmodel,
we used the rotarod test and the adhesive
removal test, two well-established func-
tional tests for this stroke model. An
analysis of functional outcome with the
per-protocol analysis revealed that senso-
rimotor deficits in both tests (at three time
points after stroke) did not differ signifi-
cantly between the sham surgery group
and either the control-treated or anti-
CD49d–treated cMCAO groups. Hence,
we were unable to discriminate between
cMCAO and sham surgery, indicating that
these commonlyused tests lacked sufficient
sensitivity to detect the limited neurologi-
cal deficits in the cMCAOmodel (fig. S2,
A to C and E). Additionally, the mean ab-
solute values for both tests differed greatly
between individual centers (fig. S2, A and
B), indicatinghigh intercenter variability inperforming these tests, despite the use of harmonized procedures. To elim-
inate intercenter variability as a source for increased variability for this
parameter, we performed a secondary analysis inwhich the poststroke def-
icitswerenormalized to their respective baseline values (fig. S2F). This anal-
ysis revealed a cMCAO-induced deficit in the adhesive removal test;
however, treatmentwith the anti-CD49d antibody had no significant effect
on this deficit. Because of the substantial behavioral deficits induced by
fMCAO, the tests used for cMCAO could not be applied in this model.
Therefore, we tested deficits in the fMCAOmodel by a composite Neu-
roscore, with no difference apparent between treatment groups (fig. S3A);
this lack of treatment effect is consistentwith the lack of treatment effect on
infarct volume in this model. The composite Neuroscore test robustly de-
tected significant deficits in the animals (compared to sham treatment) in
all five research centers 4 days after stroke. A correlation analysis of this
large cohort of animals (n = 174 fMCAO-induced mice) revealed mod-
erate correlation between infarct volume and Neuroscore outcome (r =
0.76 and r = 0.77, 2 and 4 days after stroke, respectively; fig. S3B). Although
cMCAO did not cause mortality (within 7 days after stroke), fMCAO
resulted in similar mortality rates in the control IgG–treated (16.0%) and
the anti-CD49d–treated (14.6%) groups (fig. S4). Similarly, the physiolog-
ical parameters (body temperature and body weight) were affected by
fMCAObut not by cMCAO(fig. S5). Specifically, fMCAO-induced brainFig. 3. Leukocyte brain infiltration after cMCAO and fMCAO. (A) Representative image of CD45 immu-
nohistological staining in the peri-infarct area 7 days after cMCAO. Green, CD45–Alexa Fluor 488; blue, 4′,6-
diamidino-2-phenylindole (DAPI). Scale bar, 10 mm. (B) Cumulative topographic representation of each
single CD45+ leukocyte detected on one coronal section per brain, excluding the infarct core area. Topo-
graphic maps for each section were superimposed for both treatment groups [n(IgG control): 25, n(anti-
CD49d): 27]. Total CD45+ count in ipsilateral hemispheres was 284 cells in the IgG group and 196 cells in
the anti-CD49d group. (C) Quantitative analysis of CD45+ cell count per one coronal section in ipsilateral (ip)
and contralateral (con) hemispheres of sham-operated animals (n = 30) and anti-CD49d–treated (n = 25) or
IgG control–treated (n=27)mice 7days after cMCAO. (D) Correspondingquantification of CD45+ cells 4 days
after fMCAO, sham-operated animals (n= 74), and anti-CD49d–treated (n = 49) or IgG control–treated (n= 51)
mice. Data in (C) and (D) are presented as means ± SD. (E) Linear regression analysis of CD45+ cell counts per
ipsilateral hemisphere of both treatment groups (x axis) and infarct volume (y axis) 4 days after fMCAO.
r, Pearson correlation coefficient.August 2015 Vol 7 Issue 299 299ra121 4
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surgerydidnot; however, these parameterswerenot affectedby treatment
with the anti-CD49d antibody.on
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DISCUSSION
Here, we report the results of an internationalmulticenter, randomized,
controlled, and blinded experiment for the preclinical testing of drug
efficacy. The design of this study was modeled on phase 3 clinical ran-
domized controlled trials, which are the current standard in clinical
drug development and are required to license a new drug. Our study
was performed in response to the “replication crisis” (10), the exceed-
ingly low reproducibility, and lack of robustness of preclinical results in
academic research (27–29). In addition, our approach may help to re-
solve the translational roadblock, in which promising preclinical
approaches fail to be translated to clinically effective therapies (30–32).
Thus, international research consortia—which provide larger sample sizes
with sufficient statistical power and a study design that reduces the
confounding effects of bias—have been proposed as a way to improve
the robustness and translational predictability of preclinical research
(13, 14, 33–35).
To improve the quality and reliability of preclinical research, several
international research consortia have been established, including the
European Union (EU)–funded Multi-PART (Multicentre Preclinical
Animal Research Team) consortium for stroke research and the Na-
tional Institutes of Health–funded CAESAR (Consortium for pre-
clinicAl assESsment of cARdioprotective therapies) consortium for
cardiovascular research. Systematic efforts by these consortia and others
have revealed that inadequate reporting of data, statistical flaws, and
missing cross-validation of data from independent study centers are
major flaws in preclinical translational research (5, 13, 33, 36, 37). Vir-
tually all preclinical studies performed by individual research groups are
underpowered and often fail to adequately control for bias (for example,
using randomization and blinding) (38). For example, the average
group size in more than 2000 different experiments involving more
than 35,000 rodents (in which hundreds of different treatments were
tested in ischemic strokemodels) is only 8.6 animals per group (median,
8; range, 1 to 54) (39). Ioannidis et al. (34) examined a random sample
of in vivo animal studies published since 2006 and found that fewer than
30% of studies used randomization and fewer than 10% performed a
blinded assessment of outcome; with respect to experimental stroke re-
search, these percentages are even lower (40). A meta-analysis of 49
published preclinical meta-analyses (comprising 730 primary individu-
al studies in the field of neuroscience) revealed that the median statis-
tical power was only 21% (41). This means that of 100 studies that are
conducted to investigate a genuine treatment effect, only 21 will actually
be powered in such a way as to be able to demonstrate the effect, a result
of small sample sizes. Until as recently as several decades ago, clinical
trials were challenged by the same issues that face preclinical biomedical
research today, including low internal validity, low statistical power, and
a high rate of false positives. By developing and implementing rigorous
standards for the design, execution, analysis, and reporting of studies,
today’s clinical trials can deliver robust and relevant results. Learning—
and adopting key measures—from current clinical trial design (for ex-
ample, randomization, blinding, and a priori power analysis), as in our
pRCT,may help to overcome the current crisis of preclinical translational
medicine. Such an approach has clear advantages over a meta-analysis,www.Scienwhich pools results from studies with different methodological and sta-
tistical standards, potentially differing protocols, and lack of monitoring.
In contrast, as explained in detail below, our pRCT approach aimed to
harmonize protocols and warranted a prospective, blinded, and rando-
mized study design, central monitoring of data quality, and centralized
analysis and data deposition.
Here, we used the twomost common experimental models of ische-
mic stroke to test a drug candidate that is already being tested in a phase
2 clinical trial after only a few, small-scale, single-center studies in mice.
In all but one case (8), this approach in stroke research has led until now
to costly failures and the exposure of patients to ineffective—or poten-
tially harmful—drugs (42). Many other medical fields share this frus-
trating experience. The primary objective in the design of our study
was to achieve maximum harmonization of the methods used by the
various participating study centers. The basic protocol, as well as the
primary and secondary end points, was predefined by coordination be-
tween the six laboratories. In clinical trials, patient care among various
trial sites is relatively uniform and performed in accordance with na-
tional and international guidelines. In our study, achieving harmoniza-
tion of thematerials and standard operating procedures was a challenge
in the initial phase of our study because the various laboratories gener-
ally use different strategies for testing drugs in the stroke models. We
achieved the best possible harmonization of the surgical procedures and
behavioral tests by using same-age and same-gender mice obtained
from the same commercial breeder, centrally supplying all critical
materials (for example, the filaments used to induce transient stroke),
and defining the methods used for the surgical procedures, behavioral
tests, and data acquisition. Several factors could not be harmonized ful-
ly, including the use of specific anesthetics and analgesics (a result of
differences in local regulations regarding the conduct of animal
experiments), the expertise of the surgeons, postsurgical care, body tem-
perature maintenance, and monitoring of cerebral blood flow after ves-
sel occlusion; all of these factors can potentially influence stroke
outcome. Nevertheless, comparable differences in equipment, legal re-
quirements, and the skills of the medical personnel also confoundmost
clinical RCTs. Other variables included between-site differences in the
use of sedation protocols, in postoperative anesthesia and analgesic
drugs, and in mouse microbiota.
These remainingmethodological differences might actually increase
the robustness of our obtained resultswith respect to clinical translation.
Indeed, wewere able to demonstrate that drug efficacy could be demon-
strated despite the above-mentioned procedural differences. Further-
more, increasing the sample size by pooling the efforts of multiple
laboratories reduced statistical variability and increased sensitivity of
outcome measures such as the infarct volume in the cMCAO model,
cerebral leukocyte counts, and the Neuroscore.
Another aspect of the study that was handled individually by each
study site was the approval of the animal experiments. Because of dif-
fering regulatory processes in Spain, France, Italy, and Germany, a uni-
form approval for all European partner sites was not achievable despite
the European directive 2010/63/EU. However, future pRCTs could get
approval more easily or via a single-point process for all partner sites if
pRCTs showedmore robust results than a single study andwere regarded
as a part of the preclinical evaluation of drug development.
Natalizumab, a humanized anti-CD49d antibody, is currently one of
the most effective disease-modifying drugs for multiple sclerosis (19).
With more than 7 years of clinical use, the efficacy and safety profiles
for natalizumab are well established. Themajor risk associated with thisceTranslationalMedicine.org 5 August 2015 Vol 7 Issue 299 299ra121 5
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treatment approach (the induction of progressivemultifocal leukoence-
phalopathy) usually emerges after long-term treatment, but not after a
single dose. Recently, several research groups established that lympho-
cyte invasion plays a role in stroke pathophysiology (20, 43–46). For
example, lymphocyte-deficient mice have substantially smaller lesion
volumes compared to wild-type mice (43). Therefore, targeting the
adaptive immune system is a promising therapeutic strategy for stroke.
However, the contribution of secondary neuroinflammation to post-
stroke pathophysiology is far less explored, and the translatability of
murinemechanisms to the human situation regarding stroke immunol-
ogy is still under discussion (47, 48). On the basis of previous experi-
mental studies with anti-CD49d antibodies in stroke models (20–22)
and the safety data on natalizumab use in patients with multiple sclero-
sis, a phase 2 clinical trial was initiated recently to test the effect of natalizu-
mab in patients with acute ischemic stroke [ACTION (Effect of
Natalizumab on Infarct Volume in Acute Ischemic Stroke) trial, Clinical-
Trials.gov identifier: NCT01955707]. During the ACTION trial, an animal
study was published that reported no effect of natalizumab on stroke (24),
raising concerns about the efficacy of this approach (24, 49). In contrast,
in our multicenter study, consistent with previous results (20), we found
that anti-CD49d treatment exerted amodest yet significant neuroprotec-
tive effect in the cMCAOmodel, but not in the fMCAOmodel of transient
occlusion, which causes extensive damage. Notably, this protective effect
was statistically significant when the cMCAO results were pooled from all
centers but not when analyzed in each individual center. When we pooled
results fromboth strokemodels, no significant treatment effectwasobserved.
The difference in the neuroprotective efficacy of anti-CD49d treatment
between the twomodelsmight be attributed to biological differences in the
underlying pathophysiology and/or insufficient statistical power as a result
of the unexpectedly high variability in the fMCAO model. In a head-to-
head comparison of the fMCAO and cMCAOmodels, the authors found
large differences in neuroinflammatory markers between the two models
(26). Unexpectedly, moderate-sized cortical lesions, which appeared after
permanent occlusion in the cMCAOmodel, induced higher levels of leu-
kocyte brain invasion, microgliosis, and proinflammatory cytokine release
than did the extensive hemispheric lesions of the transient ischemiamodel
(26). Consistent with these results, we also found about twofold higher ce-
rebral leukocyte counts after cMCAO than fMCAO.However, it should be
noted that different time points (4 days after fMCAO versus 7 days after
cMCAO)were used in the twomodels because of the highmortality rate in
the fMCAO-treated mice after 4 to 5 days; moreover, the cMCAOmodel
requires craniectomy and penetration of the dura. However, a recent study
by Chu et al. reported twofold higher cerebral leukocyte cell counts after
permanent occlusion by a filament in the fMCAO model compared to
transient occlusion in the same stroke model, indicating that there may
be pronounced leukocyte brain invasion in situations in which reperfusion
is not established, regardless of the strokemodel used (50). In our study, the
cerebral leukocyte counts in the anti-CD49d–treated cMCAO group (the
permanent occlusionmodel)were considerably higher than in the fMCAO
group, and we found no treatment effect of anti-CD49d on the relatively
low leukocyte numbers in the fMCAOmodel. Therefore, inhibition of the
migration of leukocytes into the brain with anti-CD49d antibodies may be
more effective in strokes that trigger amore robust inflammatory reaction.
This possibility has been generally overlooked in preclinical testing of im-
munotherapeutics for stroke, and it has also not been considered in the
design of clinical studies.
Because of its unique design (pooling results from five centers and
the unprecedented large sample size in a single preclinical experiment),www.Scienour study provides a critical view of commonly used methods in exper-
imental stroke research. The variability of outcomes differed substan-
tially between the two models; specifically, the overall SD in the
control-treated cMCAO group was 30% [mean (SD), 8.9 (2.7); n = 25
mice], which is considerably lower than the surprisingly high SD in the
control-treated fMCAO group [53%; mean (SD), 36.4 (19.9); n = 49].
Furthermore, our study also revealed an unexpectedly weak sensitivity
of some of the most widely used behavioral tests, particularly in the
cMCAOmodel, which induced only subtle neurological deficits. The ro-
tarod and adhesive tape removal tests are two of the most common tests
performed in experimental stroke research (51), and they have been suc-
cessfully used by each laboratory in our study. Nevertheless, the rotarod
test failed to detect poststroke deficits compared to sham surgery, even
after the test results were normalized to baseline values, thus excluding
intercenter differences. Moreover, the adhesive removal test results
showed wide variability, even after normalization, and therefore lacked
statistical power to detect treatment effects; nevertheless, this test was able
to detect significant deficits after cMCAO. In addition, the Neuroscore,
which was used to quantify deficits after fMCAO, also had high varia-
bility and revealed only a moderate correlation between test results and
lesion volume. It was also apparent that the laboratory with previous
experience using the Neuroscore (center 2) obtained more consistent
results with this test than did laboratories that used this test for the first
time (fig. S3). This finding might reflect a more general challenge with
respect to harmonizing procedures, which was a necessary step in
designing our pRCT. For example, deciding a priori to use mice of a
specific age or deciding to centrally distribute the surgical material
might necessitate changes in local standard operating procedures,
which, in turn, could increase variability. Nevertheless, we reasoned that
harmonizing the basic procedures and using similar materials were es-
sential for achieving a multicenter, randomized, blinded pRCT, thereby
minimizing intercenter effects and facilitating the analysis of pooled
data based on group means.
On the basis of the previous considerations and newmethodological
insights gained in our study, we were able to define several points of
potential improvement for future pRCTs: an obvious limitation for
our analysis strategy was the constraint to a per-protocol analysis,
lacking an additional intention-to-treat analysis. This is due to a sub-
stantial amount of missing data for the primary outcome measure (in-
farct volume) because of mortality or no infarct demarcation. This
might be circumvented in future studies by using inclusion criteria si-
milar to clinical trials such as imagingmodalities for confirmation of an
infarct, a defined neurological deficit range as an inclusion criterion, and
use of a behavioral readoutmarker ormortality as primary end point. In
analogy to clinical trials, which pool stroke patients with differing stroke
etiology, future pRCTsmight also consider pooling outcomeof different
models for testing drug efficacy.
One surprise in our studywas the low performance of the behavioral
tests, as well as exceedingly high variability of the fMCAO model. It
would be desirable to evaluate such methodological characteristics in
“pretrials” before future pRCTs, with the aim to validate the used
methods and grade of harmonization in-between study centers before
performing the actual pRCT. Such a pretrial would also give the oppor-
tunity to include a dose-escalation study for the investigated drug before
defining the dose for the pRCT. Finally, central assessment of behavioral
outcomes based on video recordings might reduce variability and
improve test sensitivity, which should be evaluated in a pretrial for
a future pRCT.ceTranslationalMedicine.org 5 August 2015 Vol 7 Issue 299 299ra121 6
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Given the lack of funding for international collaborative confirma-
tory research, the apparent lack of incentives for individual researchers
and laboratories, and the competitiveness associated with preclinical
biomedicine, so-called pRCT studies—although deemed necessary—are
often believed to be impossible to implement. Here, we report the fea-
sibility of this approach, despite the existence of several obstacles, and
we hope that this study will encourage researchers in all biomedical re-
search fields to consider forming similar consortia to perform essential
preclinical trials before advancing to clinical development; this ap-
proach is particularly relevant to biomedical research fields that have
traditionally been hampered by lack of reproducibility and translational
roadblock.We estimated the total full cost of our study at about €165,000
($ 180,000), includingmore than €30,000 direct drug costs (table S1). Be-
cause the use of pRCTsmay avoid unnecessary clinical trials and improve
our ability to predict successful translation, these costs for a confirmatory
study seem reasonable (52).
Our study demonstrates that poststroke treatment with anti-CD49d
antibodies confers a neuroprotective benefit in a specific mouse model
of stroke. We found differences between the results from two ischemic
stroke models with respect to cerebral leukocyte invasion and the effi-
cacy of anti-CD49d treatment; therefore, future clinical trials testing im-
munotherapeutic drugs for stroke will need to ensure that the included
study population feature a substantial neuroinflammatory reaction to
the brain injury, which may improve its potential to profit from such
therapeutic approaches. Finally, the ability of a pRCT to advance
translational research and increase the reliability of preclinical findings
should be tested by comparing the results of clinical trials with the
results of their preceding pRCTs.o
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MATERIALS AND METHODS
Study design
A key objective of this study was to implement and to test the feasibility
of performing an international pRCT in experimental biomedicine. An-
other objective was to use this pRCT approach to robustly test the neuro-
protective effect of CD49d-specific antibodies in two murine models of
experimental stroke. This study was performed from June 2013 (initi-
ation) through October 2014 (unblinding) by an international consor-
tium consisting of six independent research groups. The infarct volume
of the pooled samples from all centers and from each model was a pre-
determined primary end point of the study. The secondary end points
were functional outcome and themigration of leukocytes into the brain.
TheMunich study center (A.L.) initiated the trial, coordinated the study
design, and performed central data analysis, whereas the other five
centers [Caen (D.V.), Milan (M.-G.D.S.), Barcelona (A.M.P.), Munich
(N.P.), and Berlin (U.D. and A.R.)] contributed to study design, per-
formed the experimental part of the study, and validated centrally
determined infarct volumes. In total, 315 male C57BL/6J mice (8 to
10 weeks of age) were used [90mice for cMCAOMCAOmodel (30mice
per treated group) and 225mice for fMCAOMCAO (75mice per treated
group)]. Overall sample size per strokemodel was determined a priori by
performing a power calculation with G*Power (version 3.1) software
using the two-tailed Wilcoxon-Mann-Whitney test for two groups. For
both models, an a level of 0.05 and a power of 0.9 were required. For the
cMCAOMCAO model, a Cohen’s d ES of 0.9 was used [a conservative
assumption based on our previous results demonstrating an ES d of 1.2
(20)]. In contrast, previous studies using the fMCAOmodel in mice didwww.Sciennot detect a significant treatment effect that we could use to calculate ES.
Therefore, we assumed an ES d of 0.6 to be biologically relevant, a highly
conservative assumption based on our previous experience, which re-
vealed greater variability of infarct volume after fMCAO compared to
cMCAO. In addition, a 4-day mortality rate of 20% was assumed for
the fMCAO group. This yielded a final sample size of 29 mice per treat-
ment group for cMCAO and 63 mice per treatment group for fMCAO.
Coded samples of anti-CD49d and control antibodies, as well as some
additional items (for example, the filaments used to occlude the MCA
and the behavioral test equipment), were distributed to each study center.
The operational exclusion criteria were predefined (see below), and ana-
lytical exclusion criteria (see specifications below) were defined during
data acquisition. The mice were allocated to the treatment and surgery
groups using randomization lists generated with an online randomizer
tool (www.randomizer.org) provided by the coordinating center. Treat-
ment, surgery, analysis of infarct volume, and secondary outcomemea-
sures were performed by researchers who were blinded with respect to
the treatment groups. Unblinding was performed after the statistical
analyses were completed.Digital scans of the brain sections and all anal-
ysis files were stored on a central database that was accessible to all study
contributors. The complete set of data is reported, including outliers.
The full data set obtained from this study is publicly available at the fig-
share repository (http://dx.doi.org/10.6084/m9.figshare.1289824). The
study protocol is available in the Supplementary Materials as fig. S6.
Animals
This studywas conducted in accordancewith the respectivenational guide-
lines regarding the use of experimental animals, and all procedures were
approved by the respective government and institutional committees for
the individual research groups [Munich: RegierungspräsidiumOberbayern;
Barcelona: Ethics Committee (CEEA) of the University of Barcelona
and theDepartament d’Agricultura, Ramaderia, Pesca,Alimentació iMedi
Natural de la Generalitat de Catalunya; Milan: Institutional guidelines
and authorization by the Italian Ministry of Health; Berlin: Landesamt
fürGesundheit und Soziales, Berlin; andCaen:Regional ethics committee
of Lower Normandy]. Approval for the performed experiments was
reached at each study site by different means, such as including the ex-
periments in a 3-year laboratory program, as an addendum to an existing
license, or applying for a new license as a “proof-of-principle” study. In
total, 315male C57BL/6Jmice (8 to 10weeks of age) were supplied to the
research groups fromCharlesRiver Laboratories (stock #664). The animals
were housed in a controlled temperature (22 ± 2°C) with a 12/12-hour
light/dark cycle and access to pelleted food andwater ad libitum.Thenum-
ber of mice per cage, the use of environmental enrichment, and food type
were all determined individually by each research group in accordancewith
locally approved standard procedures. Where applicable, body weight
(measured daily) and body temperature (measured on the surgery day
and 1, 3, and 7 days after surgery) weremeasured for eachmouse. All pro-
cedures regarding the study design, animal experiments, statistical analysis,
and data reporting fulfill the criteria of theARRIVE (Animal Research: Re-
porting of In Vivo Experiments) guidelines (see checklist in the Supple-
mentary Materials as fig. S7).
Antibody treatment
Animals received an intraperitoneal injection of antibodies 3 hours after
stroke was induced (by coagulation occlusion or filament insertion);
300 mg of monoclonal mouse anti-CD49d antibody (clone R1-2,
eBioscience) or rat IgG2b isotype control antibody (clone LTF-2, BioceTranslationalMedicine.org 5 August 2015 Vol 7 Issue 299 299ra121 7
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X Cell) was diluted to 1 mg/ml in phosphate-buffered saline (PBS) and
prewarmed to 37°C before injection. The antibody concentration was
chosen on the basis of information in two previous reports that used
the same antibody clone in experimental stroke models (20, 24).
Transient MCAO (fMCAO) model
Animals were anesthetized with isoflurane in a 30 to 70% mixture of O2
andN2O, and the temporal bonewas exposedwith an incisionbetween the
ear and the eye. A laserDoppler probe (at centers 1, 3, and 4)was affixed to
the skull above the MCA territory. The animal was then placed in the su-
pine position. Using a midline neck incision, the common carotid artery
and the external carotid artery (right side, groups 1 to 3; left side, groups 4
and 5) were isolated and ligated; a 2-mm silicon-coated filament
(#701912PK5Re, Doccol) was threaded into the internal carotid artery,
and MCA occlusion was confirmed by a reduction in the corresponding
laser Doppler flow. After 60min of occlusion, the animals were reanesthe-
tized, and the filament was removed. For the postsurgical survival period,
the animalswere housed in their home cageswith access towater and food.
Sham-operated control mice received the same surgical procedure, except
the filament was not inserted. Body temperature was maintained during
surgery using a feedback-controlled heating pad. Analgesia was provided
during surgery and in the postoperative phase in accordance with each
center’s local regulations.
Surgical exclusion criteria: Centers 1, 3, and 4 used laser Doppler flow
during the operation to confirm sufficient MCA occlusion (a reduction in
blood flow to <20% of the baseline value). In addition, at all five contribut-
ing centers, mice that did not develop sufficient neurological deficits
(that is, Neuroscore <8) 24 or 48 hours afterMCAOwere excluded.Mice
that died during the observation period were excluded from all analyses,
but differences in themortality rate between the treatment groups during
the observation period were determined.
Permanent MCAO (cMCAO) model
Centers 1, 2, and 3 performed the cMCAO procedure as described (53).
In brief, the animals were anesthetized with isoflurane in a 30 to 70%
mixture of O2 and N2O and placed in a lateral position. The skin was
incised between the eye and the ear, the temporal muscle was removed,
and theMCAwas identified. A burr holewas drilled over theMCA, and
the dura mater was removed carefully. The MCA was permanently oc-
cluded with either bipolar electrocoagulation forceps or an electrocau-
terizer. Permanent occlusion of theMCAwas confirmed visually before
closing the wound with sutures. During surgery, body temperature was
maintained using a feedback-controlled heating pad. Sham-operated
mice received the same surgical procedure without MCA coagulation.
Surgical exclusion criteria:Mice that developed a subarachnoid hemor-
rhage during surgery were excluded from the analysis. In addition, mice
that died during the observation period were excluded from analysis.
Functional outcome tests
The rotarod and adhesive removal tests were performed 1, 3, and 7 days
after cMCAO. These tests were chosen because they are the most
commonly used tests for measuring the effect of cMCAO, which results
in onlyminor behavioral deficits, and because these tests were used pre-
viously by all three centers that performed the cMCAO model.
The rotarod test was used to measure coordination and sensorimotor
performance before and after cMCAO (54). Mice were trained daily for
3 days before MCAO or sham surgery, and baseline performance was
recorded the day before cMCAO using the following strategy: the rodwww.Scienaccelerated from 8 to 40 rpm over 240 s, with a mean of three consec-
utive trials permouse and time points. The latency to fall off the rodwas
recorded, and postsurgical performance was calculated by dividing the
postsurgical values by the individual animal’s baseline performance.
The adhesive removal test was used to evaluate sensory andmotor def-
icits (55). A round (4-mm-diameter) adhesive sticker was placed on the
palmar side of the forepaw; the samepressurewas applied for each adhesive
application. The day before surgery (and at the indicated times after
cMCAOor shamsurgery), three trials per testwereperformed.The latency
to contact thepawwith the adhesive and the latency to remove the adhesive
were recorded.Motorperformancewasexpressedas thedifferencebetween
the latency to contact the paw and the latency to remove the adhesive.
The Neuroscore was performed before surgery and 2 and 4 days af-
ter fMCAO or sham surgery; this test was used to evaluate the general
status and focal neurologic dysfunction after fMCAO, which induces
substantial deficits in contrast to the cMCAOmodel, andwas performed
as described (56). The score ranges from0 (nodeficits) to 56 (representing
the poorest performance in all items) and is calculated as the sum of
the general and focal deficits. The Neuroscore results were expressed
as a composite neurological score, which included the following general
deficits (scores): fur (0 to 2), ears (0 to 2), eyes (0 to 4), posture (0 to 4),
spontaneous activity (0 to 4), and epileptic behavior (0 to 12); and the
following focal deficits: body asymmetry (0 to 4), gait (0 to 4), climbing
on a surface inclined at 45° (0 to 4), circling behavior (0 to 4), front-limb
symmetry (0 to 4), circling behavior (0 to 4), and whisker response to
light touch (0 to 4).
Tissue sampling and processing
Mice were deeply anesthetized 7 days after cMCAO, 4 days after fMCAO,
and at the respective times for mice in the corresponding sham surgery
groups. The brain was removed, frozen immediately on powdered dry
ice, and stored at −20°C. All biological samples were shipped on dry ice
to the central analysis center in Munich, where the samples were stored
at −80°C until further analysis and for central archiving. All brains were
cryosectioned by researchers who were blinded with respect to the surgery
and treatment groups. Coronal brain sections (20 mmthick)were prepared
at 400-mm intervals and used to analyze infarct volume. In addition, 12-m
m-thick coronal sectionswere obtained at the level of the anterior commis-
sure andwere used for immunohistochemistry. Sectionsweremounted on
Superfrost Plus slides (Thermo Scientific) and stored at −80°C.
Infarct volumetry
Infarct volume was measured in CV-stained sections as described (53).
In brief, one series of serial (20-mm-thick) sections from each animal
was air-dried at room temperature for 30 min. The slides were stained
with a 0.1% CV solution at 60°C for 10 min and then rinsed twice in
distilled water for 1min. After washing and dehydration, the slides were
covered with Roti-Histokit mounting medium (Roth). CV-stained
sections were scanned at 600 dpi on a flatbed scanner (LiDE 210,
Canon). For the cMCAO model, the direct infarct demarcation on CV-
stained sections (unstained area) was measured after confirming the ab-
sence of edema at the investigated time point (7 days after cMCAO or
sham surgery). For the fMCAO model, we corrected the infarct vol-
ume for edema with the following equation: (Ischemic area) = (Direct
lesion volume)− [(Ipsilateral hemisphere)− (Contralateral hemisphere)].
In both models, total infarct volume was determined by integrating the
measured areas and distances over the sections. To validate the sections
in the MCAO mice with missing lesion demarcation on CV staining,ceTranslationalMedicine.org 5 August 2015 Vol 7 Issue 299 299ra121 8
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neuronal loss was measured with the terminal deoxynucleotidyl trans-
ferase–mediated deoxyuridine triphosphate nick end labeling (TUNEL)
method (TUNELApoptosisDetectionKit,Millipore). All sectionswere
analyzed independently by two central investigators (G.L. and A.L.),
both of whom were blinded with respect to the treatment groups; the
mean of these two measurements was used for subsequent analyses. In
addition, the original CV-stained slides were returned to the respective
originating center for further validation. Interrater reliability between
the two central investigators and the individual participating centers
was measured and is shown in fig. S1.
Analytical exclusion criteria: The following criteria were used to ex-
clude samples from the analysis: (i) missing biological samples due to
the death of an animal before the study’s end point (day 4 for fMCAO
and day 7 for cMCAO; n = 23mice excluded); (ii) overt mechanical dam-
age or disruptionwhen preparing the brain sections, rendering the sample
unusable (n= 2mice excluded); (iii) no ischemic brain lesion detectable in
the MCAO group (detected as demarcation on CV staining or no neuro-
nal apoptosis measured using TUNEL staining) (n = 27 mice excluded);
(iv) demarcation of an ischemic lesion on CV-stained sections in sham-
operated mice (n = 2 mice excluded); and (v) Neuroscore <8 points
24 hours after fMCAO (n = 6mice excluded). The individual animals that
were excludedon thebasisof the aforementionedcriteriawere also excluded
from the analysis of behavioral data sets and physiological parameters.
Immunofluorescence
We performed immunofluorescence staining for CD45 to identify leu-
kocytes that had infiltrated the brain. Coronal sections (12 mm thick)
were prepared at the level of the anterior commissure and dried at room
temperature for 1 hour. After rinsing in PBS (pH 7.4), the slides were
fixed with acetone at −20°C, rinsed in PBS, and incubated in blocking
buffer (BB) containing 0.1% Triton, 0.05%Tween 20, 10% fetal calf ser-
um, and 1% bovine serum albumin (w/v) in PBS at room temperature
for 1 hour. The slides were then incubated overnight at 4°C in anti-
CD45 antibody (1:100, clone 104-2, Abcam) in BB. The slides were then
rinsed in PBS and incubated for 1 hour at room temperature in Alexa
Fluor 488 goat anti-mouse IgG (H+L) (1:100, Invitrogen). Finally, the
slides were rinsed in PBS, counterstained for 2 min with DAPI (1:4000,
Invitrogen), and mounted using Fluoromount medium (Sigma). The
slides were analyzed using an epifluorescence microscope (Axiovert
200M, Zeiss). CD45-positive cells were counted in one 12-mm section
per brain at the position of the anterior commissure (about 0.1mm ros-
tral to bregma). The infarct core was identified with corresponding
CV-stained sections, and this area was excluded from the localization
analysis and quantification of CD45-positive cells. For the cMCAO
model, the location of each CD45-positive cell was marked on a topo-
graphic map according to the mouse brain atlas, yielding a cumulative
localization map of leukocyte invasion for each treatment group.
Statistical analysis
This study was designed as a prospective, multicenter, randomized
controlled trial of experimental ischemic stroke induced in mice via
two distinct models. The above-mentioned operational and analytical
exclusion criteria were applied. If a mouse met one or more of the ex-
clusion criteria, data and samples were excluded from all analyses. Suf-
ficient normal distribution of all data sets was verified by checking
histograms (unimodal distribution) and skewness (|skewness| <1).
Physiological parameters and cerebral leukocyte counts were analyzed
by ANOVA followed by Tukey’s multiple-comparison test (GraphPadwww.ScienPrism 6.0). The characteristics of the samples obtained from the indi-
vidual centers (Table 1)were testedwith Fisher’s exact test, thec2 test, or
ANOVA (where indicated), and mortality was analyzed by comparing
the survival curveswith the log-rank (that is,Mantel-Cox) test (GraphPad
Prism 6.0). Infarct volume and behavioral deficits were tested using a
linear mixed-effects model to account for heterogeneity between centers
(SPSS version 22, IBM). We used random intercept models with treat-
ment group as the independent variable and infarct volume as the
dependent variable. ES estimates (standardized mean difference) were
calculated using inverse-variance weighting in a random-effects model
using RevMan version 5.3; RevMan 5.3 was also used to create the forest
plot in Fig. 2C. Correlation analysis for infarct volume and behavioral
deficits was performed using linear regression (GraphPad Prism). Con-
cordance analysis for interrater reliability was done using the Bland-
Altman method (GraphPad Prism) and calculation of ICCs (SPSS).
A two-sided significance level of a = 0.05 for both primary hypothe-
ses was applied. P values for secondary hypotheses should be inter-
preted cautiously as exploratory analyses. No adjustment for duality
of the two strokemodels was applied. An overview ofmeans and 95%
CI is available for all primary and secondary end points in table S2.SUPPLEMENTARY MATERIALS
www.sciencetranslationalmedicine.org/cgi/content/full/7/299/299ra121/DC1
Fig. S1. Analyses for interrater concordance.
Fig. S2. Behavioral tests before and after cMCAO.
Fig. S3. Composite Neuroscore for functional deficits after fMCAO.
Fig. S4. Mortality after cMCAO and fMCAO.
Fig. S5. Physiological parameter analysis after cMCAO and fMCAO.
Fig. S6. Study protocol.
Fig. S7. The ARRIVE guidelines checklist.
Table S1. Study costs (in euro).
Table S2. fMCAO and cMCAO means and CIs.REFERENCES AND NOTES
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Fig. S1. Analyses for interrater concordance. (A) Concordance of infarct volume 
measurements was assessed in between the two independent raters at the central study 
center. Analyses confirmed excellent inter-rater concordance within the central study 
center. (B) Concordance was determined between the mean infarct volume (mm3) of the 
central study center and the individual experimental centers. n(Center 1): 40; n(Center 
2): 32; n(Center 3): 36; n(Center 4):30; n(Center 5): 16. Concordance was estimated by 
intra class correlation coefficient (ICC) and 95% confidence intervals [CI].  
Figure S1 
Infarct vol. rater 1 (mm3) 
In
fa
rc
t v
ol
. r
at
er
 2
 (m
m
3 )
 
150 
150 
100 
100 
50 
50 
0 
0 
ICC = 0.99 
[0.990-0.994] 
ICC = 0.96 
[0.93-0.97] 
ICC = 0.88 
[0.65-0.95] 
ICC = 0.99 
[0.98-0.99] 
ICC = 0.97 
[0.78-0.99] 
ICC = 0.92 
[0.67-0.97] 
	  
Sham 
IgG control 
anti-CD49d 
A 
B 
2.0 
1.5 
1.0 
0.5 
0 
1 3 7 
1 3 7 
0 
Days after cMCAO 
Days after cMCAO 
Fa
ll 
la
te
nc
y 
(r
at
io
 to
 B
L)
 
Fig. S2. Behavioral tests before and after cMCAO. 
Motor deficits were determined before and 1, 3 and 7 
days after cMCAO, using (A and C-D) the Rotarod 
system and (B and E-F) the adhesive removal test. 
Results are presented per individual center (A, B) and 
as pooled samples from all centers (C-F). Results for 
pooled samples were presented as raw data as pre-
defined in the analysis strategy (C, E) and as secondary 
normalization of individual post-stroke values to 
baseline performance before MCAO. (D, F). Data are 
presented as mean ±SD. BL: baseline. *: p<0.05 
between sham and the indicated cMCAO group at the 
respective time point. (Center 1: n(Sham): 10; n(IgG 
Control): 2; n(anti-CD49d): 2. Center 2: n(Sham): 9; 
n(IgG Control): 1; n(anti-CD49d): 5. Center 3: 
n(Sham): 10; n(IgG Control): 10; n(anti-CD49d): 10). 
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Fig. S3. Composite Neuroscore for functional deficits after fMCAO. (A) Each panel depicts results for the composite Neuroscore before fMCAO and 2 
and 4 days after fMCAO per individual center and as pooled samples from all centers. * : p<0.05 between sham and the indicate cMCAO group at the 
respective time point. Data are presented as mean ±SD. (Center 1: n(Sham): 14; n(IgG Control): 11; n(anti-CD49d): 9. Center 2: n(Sham): 15; n(IgG 
Control): 6;  n(anti-CD49d): 9. Center 3: n(Sham): 15; n(IgG Control): 12; n(anti-CD49d): 9. Center 4: n(Sham): 15; n(IgG Control): 15; n(anti-CD49d): 
15. Center 5: n(Sham): 15; n(IgG Control): 5; n(anti-CD49d): 9). (B) Correlation of infarct volume and functional deficit as assessed by the composite 
Neuroscore was analyzed by linear regression for results at day 2 and 4 after fMCAO, respectively. n(Sham): 74; n(IgG Control): 49; n(anti-CD49d): 51. 
r=Pearson correlation coefficient.   
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Fig. S4. Mortality after cMCAO and fMCAO. Mortality during the observation period is depicted as Kaplan-Meier curves. (A) We did not 
observe any post-operative mortality during the 7d observation period after cMCAO (control or anti-CD49d group) and the respective sham 
surgery. n(Sham): 30; n(IgG Control): 25; n(anti-CD49d): 27. (B) fMCAO induced a moderate mortality in both treatment groups without a 
significant difference between treatment during the 4d observation period. n(Sham): 74; n(IgG Control): 49; n(anti-CD49d): 51. 
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presented as mean ±SD. BL: baseline. * : p<0.05 of the indicated MCAO group compared to the respective sham group. cMCAO: n(Sham): 30; n(IgG 
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Fig. S6. Study Protocol 
 
Multicenter Anti-CD49d trial, FINAL v2 
October, 16th 2013 
 
Experimental groups: A. Planas, M.G. de Simoni, N. Plesnila, U. Dirnagl, D.Vivien 
Facilitator and analysis centre: A. Liesz 
 
Models: 
1) 60min Filament-MCAO, mice awake during occlusion period, (15 mice per treatment groups + 15 
Sham): all groups (total: 150 MCAO mice + 75 Sham) 
2) Transcranial MCA-Coagulation model (10 per treatment groups + 10 Sham): Planas, de Simoni, 
Vivien (total: 60 MCAO mice + 30 Sham) 
 
3 groups per model: 
1) Sham-operation, no treatment 
2) Verum: 300 µg Anti-Mouse CD49d (Clone R1-2) 
3) Placebo: 300 µg Rat IgG2b isotype control (Clone: LTF-2) 
 
 
PROTOCOL: 
 
1) Antibody samples sent blinded (Vial A and B) to experimental groups 
• Antibody concentrations (verum and isotype) is set to 1mg/ml 
• Store at 4°C until use 
• à 300 µl i.p. injection per mouse 
 
2) Doccol filaments sent to groups (10 filaments per group) 
 
3) Experimental protocol: 
• 8-10 week old male C57Bl/6J mice (Charles River, stock # 664) 
• Random allocation list to treatment groups sent by the facilitator (e.g. ABBBAABA …) 
• i.p. injection of the antibody (after pre-warming to 37°C) 3h after MCAO-induction (i.e. 
after MCA coagulation or filament insertion) 
 
• Inclusion criteria: 
o Filament model: reduction in doppler flow to <20% after filament insertion 
compared to original values OR circling behavior during occlusion time and 
Bederson score ≥ 1 at 24h after MCAO 
o Coagulation model: visualized and controlled (after 1min) total occlusion of the 
MCA branch 
• Exclusion criteria (Surgical) 
o Both models: Bite wound before inclusion, exclusion due to excessive weight loss 
>35% compared to day -1 (à sacrification)  
o Filament model: insufficient doppler flow reduction or missing functional deficit 
during occlusion time and at 24h after MCAO 
o Coagulation model: incomplete MCA branch occlusion, subarachnoid bleeding 
during operation 
• Exclusion criteria (Analytical) 
o Both models: major protocol violation (e.g. no drug applied, wrong occlusion time, 
etc.); death 
o Filament MCAO: Neuroscore at 24h below 8 Points; No cortical infarct 
demarcation (no infarct at all [incl. TUNEL neg.]  
o Coagulation MCAO: no infarct demarcation (no infarct at all [incl. TUNEL neg.] 
 
• General operational procedures: Filaments by Doccol will be provided 
(Cat.#  602123PK10 ), volatile anesthesia (induction: 4%, operation: 2% isoflurane, mixed 
in 70% 02 / 30 % N20), feedback controlled heating during operation, mice awake during 
filament-occlusion time (60min), warming of mice during occlusion time (filament MCAO) 
and post-operation recovery for 2h, simplified access to water and food after Filament-
MCAO (e.g. in dish on cage bottom), mice placed back in same cages with same mates 
after MCAO as before, post-operation analgesia according to individual protocols 
• Survival:  
o Coagulation model: 7d (= one week; e.g. Monday à Monday) 
o 60min Filament-MCAO: 4d (= 96h; e.g. Monday à Friday) 
• Daily measurement of: weight and mortality (please document time point of death!) 
• Body temperature:  Coagulation: d-1, d1, d3 and d7 
Filament: d-1, d2, d4 
• Behavior tests (protocols below) : 
o Filament model: “Ischemia Neuroscore” (d-1, d2 and d4) 
o Coagulation model: Sticky label test and Rotarod (d-1, d1, d3, d7)  
• Sacrifice 7d or 4d after MCAO, respectively:  
o Collecting plasma: cardial puncture and transfer blood to EDTA test tubes (will be 
provided); centrifuge for 15min at 2,000g; transfer plasma to Eppi 
o perfusion with saline (no fixation or sucrose rinse) 
o collecting spleens and brains 
o brains and spleens frozen on powdered dry ice  
4) Frozen brains sent blinded (e.g. 1,2,3,…) on dry ice to A. Liesz, plasma and spleens remain 
preliminary with individual groups until further analysis 
5) Central (blinded) sectioning (20µm each 400µm), staining (cresyl violet) and infarct volumetry 
of all brains by the same method 
6) Additional sections (12µm) at the anterior commissure for later histological analyses 
(leukocytes and neuronal density) 
7) Scanned brain slides uploaded to a shared online storage and original slides sent back to 
respective experimental group for counter-evaluation 
8) Experimental groups unblinded for treatment à Unblinding of mouse allocation to treatment 
group (e.g. 1=A, 2=A, 3=B, …) 
 
9) Final data analysis 
• Primary end points: Infarct volume of pooled samples per model 
• Secondary end points: 
o Mortality in the 60min F-MCAO model 
o Behavioral Tests between 3 groups: 2x treatment and Sham 
o Neuronal density between treatment groups per model 
o Brain leukocyte invasion between treatment groups per model 
o Systemic immune parameters (cytokine expression) between  
§ a) 3 groups: 2x treatment and Sham 
§ b) between models 
 
 
BEHAVIORAL TESTS 
 
Composite Neuroscore (for 60min fMCAO): 
Scores range from 0 (healthy) to 56 (the worst performance in all categories) and represent the sum of the results 
of general and focal deficits (13 categories). Results are expressed as a composite neurological score. 
 
These include general deficits: hair (0–2), ears (0–2), eyes (0–4), posture (0–4), spontaneous activity (0–4), and 
epileptic behavior (0–12), and focal deficits: body symmetry (0–4), gait (0–4), climbing on a surface held at 
45°(0–4), circling behavior (0–4), front limb symmetry (0–4), compulsory circling(0–4), and whisker response to 
a light touch (0–4) 
 
1. Hair (score 0-2) 
Mouse on open bench top (OBT). Observation with no interference.  
0- Hair neat and clean.       
1- Localized piloerection and dirty hair in 2 body parts (typically nose and eyes).  
2- Piloerection and dirty hair in more than 2 body parts.      
2. Ears (score 0-2) 
Mouse on OBT. Observation at the beginning with no interference, then stimulating by snapping fingers.  
0- Normal. Ears are stretched laterally and behind. They react to noise. 
1- Stretched laterally but not behind (one or both). They react to noise.  
2- Same as 1 but they do not react to noise.      
 
3. Eyes (score 0-4) 
Mouse on OBT. Observation with no interference or stimulation. 
0- Open, clean and quickly follow the surrounding environment.    
1- Open and characterized by aqueous mucus. Slowly follow the surrounding environment. 
2- Open and characterized by dark mucus.      
3- Ellipsoidal shaped and characterized by dark mucus.     
4- Closed.      
      
4. Posture (score 0-4) 
Place the mouse on the palm and swing gently.    
0- The mouse stands in the upright position with the back parallel to the palm. During the swing,  it stands 
rapidly.      
1- The mouse stands humpbacked. During the swing,  it flattens the body to gain stability. 
2- The head or part of the trunk lies on the palm.      
3- The mouse lies on one side, barely able to recover the upright position.  
4- The mouse lies in a prone position, not able to recover the upright position.    
      
5. Spontaneous activity (score 0-4) 
Mouse on OBT. Observation with no interference or stimulation.   
0- The mouse is alert and explores actively.      
1- The mouse seems alert, but it is calm and sluggish.     
2- The mouse explores intermittently and sluggishly.      
3- The mouse is somnolent and numb, few movements on-the-spot.   
4- No spontaneous movements.    
      
 
6. Epileptic behavior (score 0-12) 
Mouse on OBT. The worse epileptic behavior detected during the whole observational period should be recorded 
and reported according to the following score. 
0- None.     
3- The mouse is reluctant to handling, shows hyperactivity.   
6- The mouse is aggressive, stressed and stares.     
9- The mouse shows hyperexcitability, chaotic movements and presence of convulsion following handling. 
12- Generalized seizures associated with wheezing and unconsciousness.    
      
    
FOCAL DEFICITS (total score 0-28) 
 
7. Body symmetry (score 0-4) 
Mouse on OBT, observation of undisturbed resting behavior and description of the virtual nose-tail line 
0- Normal.  
a. Body: normal posture, trunk elevated from the bench, with fore and hindlimbs leaning beneath the body  
b. Tail: straight 
1- Slight asymmetry.  
a. Body: leans on one side with fore and hindlimbs leaning beneath the body 
b. Tail: slightly bent 
2- Moderate asymmetry.  
a. Body: leans on one side with fore and hindlimbs stretched out  
b. Tail: slightly bent 
3- Prominent asymmetry.  
a. Body: bent, on one side lies on the OBT 
b. Tail: bent 
4- Extreme asymmetry. 
a. Body: highly bent, on one side constantly lies on the OBT 
b. Tail: highly bent 
 
8. Gait (score 0-4) 
Mouse on OBT. Observation of undisturbed movements. 
0- Normal. Gait is flexible, symmetric and quick. 
1- Stiff, inflexible. The mouse walks humpbacked, slower than normal mice. 
2- Limping with asymmetric movements. 
3- Trembling, drifting, falling. 
4- Does not walk spontaneously. (In this case,   stimulation will be performed gently pushing the mouse with a 
pen. When stimulated, the mouse walks no longer than three steps)   
 
 
9. Climbing (score 0-4) 
Mouse on a gripping surface 45° to OBT. Place the mouse in the centre of the gripping surface. 
0- Normal. The mouse climbs quickly. 
1- Climbs with strain, limb weakness present. 
2- Holds onto slope, does not slip or climb. 
3- Slides down slope, unsuccessful effort to prevent fail. 
4- Slides immediately, no effort to prevent fail. 
 
 
10. Circling behavior (score 0-4) 
Mouse on OBT. Observation of the mouse walking undisturbed on the OBT. 
 0- Absent. The mouse equally turns left or right.  
1- Predominantly one-sided turns.  
2- Circles to one side, although not constantly. 
3- Circles constantly to one side. 
4- Pivoting, swaying, or no movement. 
 
11. Forelimb symmetry (score 0-4) 
Mouse suspended by the tail. Movements and position of forelimbs are observed.  
0- Normal. Both forelimbs are extended towards the bench and move actively. 
1- Light asymmetry. Contralateral forelimb does not extend entirely. 
2- Marked asymmetry. Contralateral forelimb bends towards the trunk. The body slightly bends on the ipsilateral 
side. 
3- Prominent asymmetry. Contralateral forelimb adheres to the trunk.  
4- Slight asymmetry, no body/limb movement.  
 
 
12. Compulsory circling (score 0-4) 
Forelimbs on bench, hindlimbs suspended by the tail. This position reveals the presence of the contralateral limb 
palsy. 
0- Absent. Normal extension of both forelimbs. 
1- Tendency to turn to one side. The mouse extends both forelimbs, but starts to turn preferably to one side. 
2- Circles to one side. The mouse turns towards one side with a slower movement compared to healthy mice. 
3- Pivots to one side sluggishly. The mouse turns towards one side failing to perform a complete circle. 
4- Does not advance. The front part of the trunk lies on the bench. Slow and brief movements.  
 
 
13. Whisker response (score 0-4) 
Mouse on the bench. Using a pen, touch gently the whiskers and the tip of the ears from behind, first one the 
lesioned and then on the contralateral side.  
0- Normal symmetrical response. The mouse turns the head towards the stimulated side and withdraws from the 
stimulus.  
1- Light asymmetry. The mouse withdraws slowly when stimulated on the ischemic side. Normal response on 
the contralateral side. 
2- Prominent asymmetry. No response when stimulated on the ischemic side. Normal response on the 
contralateral side. 
3- Absent response ipsilaterally, slow response when stimulated on the contralateral side. 
4- Absent response bilaterally. 
 
 
 
 
 
 
Rotarod (for cMCAO): 
 
• Rotation protocol: 4min acceleration time (ramp time), 8-40rpm (min – max)  
o Start rotarod at 4rpm 
o Place all mice on rough rods 
o Start acceleration 
o Document latency to fall for each individual 
o If a mouse clings to the rod: stop the timer after 2 full passive rotations 
• 3 runs per test, 15min pause interval between the runs 
• Training of animals on 3 consecutive days before the operation is required 
• Baseline measurement on day-1;  
• Deficit analysis at 24h, 72h and on day 7 after MCAO. 
• Report the raw data of latency to fall/passive rotation at baseline and at tests after MCAO for both runs 
 
Template, which should be used for data acquisition: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sticky label test (for cMCAO): 
 
Training: Do a few times 1 day before surgery  
 
1. Place mouse in box for 2 mins for it to become accustomed to the new surroundings, and so that it looks 
around and loses its curiosity 
2. Fix the mouse in your hand and place sticker on one palm (press tightly to make sure it is on properly) 
3. Release the mouse from fixation and place carefully in the box. Start timer. 
4. Count for a maximum of 2 minutes 
5. Record when the mouse first shakes its paw (shake), when it first lifts its paw to its mouth (contact), and 
when it removes the sticker (remove). 
6. Repeat 3 times and average (interchanging between left and right paw each time). 
7. Clean box with a little bit of alcohol before placing the next mouse into the box. 
 
Template, which should be used for data acquisition: 
 
Training      Test        Test       
            
Date:    Date:    Date:   
  L R   L R   L R 
Shake      Shake      Shake     
Contact      Contact      Contact     
Remove      Remove      Remove     
            
Shake      Shake      Shake     
Contact      Contact      Contact     
Remove      Remove      Remove     
            
Shake      Shake      Shake     
Contact      Contact      Contact     
Remove      Remove      Remove     
 
 
 
Test        Test       
       
Date:    Date:   
 L R   L R 
Shake      Shake     
Contact      Contact     
Remove      Remove     
       
Shake      Shake     
Contact      Contact     
Remove      Remove     
       
Shake      Shake     
Contact      Contact     
Remove      Remove     
 
 
 Supplementary Material  S7 
 
 Supplementary Material  S7 
 
	  
Table S1. Study costs (in uro
Study 
center 
Center 1 Center 2 Center 3 Center 4 Center 5 Total 
Personnel 32,037 19,454 20,200 20,000 2,015 4,410 98,116 
Animals 0 3,731 1,000 5,954 900 1,440 13,025 
Antibodies and 
consumables 
34,475 1,380 1,000 296 0 2,790 39,942 
Shipping and 
others 
2,685 1000 7,200 2,687 0 627 14,199 
Total 69,198 25,565 29,400 28,937 2,195 9,267 165,282 
e ).
	  Table S2. fMCAO and cMCAO mean and CI
 
fMCAO cMCAO 
Sham IgGControl CD49d Sham IgGControl CD49d 
Number of 
animals 74 49 51 30 25 27 
Infarct volume 0 36.78            
[31.17-42.39] 
35.76            
[31.19-40.34] 0 
8.87        
[7.76-9.98] 
7.20      
[6.03-8.38] 
CD45+ cells 
ipsilateral 
hemisphere 
1.54              
[1.00-2.07] 
5.38            
[4.29-6.46] 
5.53          
[4.63-6.43] 
1.034            
[0.48-1.59] 
11.36            
[9.57-13.15] 
7.26          
[6.04-8.80] 
Neuroscore d2 4.15              
[2.94-5.36] 
16.69            
[14.38-19.01] 
16.35         
[13.94-18.76] - - - 
Neuroscore d4 3.32            
[2.39-4.26] 
17.29           
[14.93-19.64] 
15.06            
[12.87-17.24] - - - 
Rotarod test BL - - - 138.50      
[113.2-163.8] 
108.70      
[79.42-138.0] 
132.10      
[98.00-166.1] 
Rotarod test d1 - - - 142.90       
[117.1-168.6] 
123.1      
[91.59-154.7] 
137.30      
[103.1-171.5] 
Rotarod test d3 - - - 139.30        
[111.8-166.9] 
129.0       
[99.05-159] 
146.40       
[112.7-180.2] 
Rotarod test d7 - - - 138.90        
[111.1-166.6] 
139.50        
[109.1-169.8] 
152.70        
[123.2-182.2] 
Adhesive 
removal test BL - - - 
2.35            
[1.34-3.30] 
0.99              
[0.53-1.44] 
1.24              
[0.64-1.84] 
Adhesive 
removal test d1 - - - 
1.28                
[0.77-1.80] 
2.15              
[0.54-3.75] 
2.70               
[0.46-4.95] 
Adhesive 
removal test d3 - - - 
1.44                 
[0.81-2.06] 
3.73               
[0.69-6.77] 
3.93            
[13.20-6.53] 
Adhesive 
removal test d7 - - - 
2.42             
[0.55-4.29] 
4.12             
[1.35-6.89] 
2.11                
[1.03-3.19] 
s  s .
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